Adherence in HIV-positive women entering antenatal care on antiretroviral therapy: A cross-sectional study by O'Sullivan, Briana Jean
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
Adherence in HIV-Positive Women 
Entering Antenatal Care on Antiretroviral 
Therapy: A Cross-sectional Study 
 
 
 
 
Manuscript for dissertation requirement for a  
Master’s of Public Health 
 
 
 
Author: Briana O’Sullivan 
OSLBRI001 
 
 
 
Submitted in fulfillment of the requirements for the degree 
 
MASTER OF PUBLIC HEALTH 
 
In the 
 
SCHOOL OF PUBLIC HEALTH AND FAMILY MEDICINE 
 
 
 
Advisor: Landon Myer 
 
 
 
 
 
 
 
 
June 2015 
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
Plagiarism Declaration 
 
 
I, Briana O’Sullivan (OSLBRI001), hereby declare that the work which this dissertation is 
based is my original work (except where acknowledgements indicate otherwise) and that 
neither the whole work nor any part of it has been, is being or is to be submitted for 
another degree in this or any other university. 
 
I empower the university to reproduce for the purpose of research either the whole or any 
portion of the contents in any manner whatsoever. 
 
 
 
Signature  
 
 
Date          18 November, 2015 
Dedication Page 
 
 
For Mel, who I hope would be proud. 
Abstract 
 
 
 
Proper implementation of and adherence to antiretroviral therapy (ART) is significantly associated 
with better health and longer life in HIV-positive individuals. Consistent, adequate adherence has been 
shown to lead to a suppressed viral load. A low viral load delays the virus’s progression and leads to better 
health outcomes for the individual.  
 
Adequate adherence is especially important among HIV-positive pregnant women. How well a 
woman adheres to her ART can not only improve her health during pregnancy but can protect the infant from 
HIV by preventing in utero transmission of the virus. Continuing ART protects against transmission via 
breastmilk later in the infant’s life.  
 
While the benefits of good adherence are undeniable, the definition of adequate adherence varies 
widely in the literature. Taking 80 to 100 % of pills as prescribed is commonly used as the threshold for 
adequate adherence levels. Various methods exist for measuring ART adherence, and while some are more 
reliable than others, there is no gold standard.  
 
This ambiguity in ART research extends to pregnant women, with even less known about HIV-
infected women established already on ART who then become pregnant. Changes in treatment protocols in 
the Western Cape and improvement of ART delivery throughout South Africa have resulted in this group of 
long-term users growing in size. Without more research into the barriers of ART adherence in these women, 
efforts to scale up treatment programs and to end mother to child transmission of HIV will ultimately fail. This 
dissertation is an exploration of these ideas. It begins to fill the gap in current knowledge related to ART 
compliance in pregnant women, and gives new insights into how specific barriers to adherence can 
adversely affect this specific group of established ART users.  
 
Part A is a research proposal. It presents an analysis of data collected from Phase 1 of the Maternal 
and Child Health Antiretroviral Treatment study (MCH-ART). This phase, with participant enrolment from 
April 2013 through May 2014, was a cross-sectional survey of women attending their first visit at a midwife 
obstetric unit in Gugulethu, Western Cape. The protocol proposes an analysis of a subgroup of this sample, 
consisting of 486 women who initiated ART prior to their current pregnancy. Included in this section is also a 
weighing of the possible benefits, harms and ethical issues with this secondary analysis. 
 
Part B is a review of the literature, examining issues around adherence to ART. Special attention is 
given to studies that include pregnant women and women who are long-time users of ART. This literature 
review serves to explain the issues around defining adherence in research; to explore various methods of 
measuring adherence and their reliability; and to identify and give some background on potential risk factors 
measured in the MCH-ART study for poor adherence to ART in pregnancy. 
 
Part C is the research article, which is made up of four sections: background, methods, results and 
discussion. This article features a quantitative analysis of the data described in Part A, with univariate and 
bivariate descriptions of the population. Reliability of various self-reported measures of adherence is 
explored to validate the chosen self-reported adherence measure. Cronbach’s alphas are generated for the 
scale measures used in Phase 1 to assess their validity and reliability in this population. Finally a model that 
describes the barriers to adherence among this important group of women is built using variables identified 
in Part B as potential risk factors for poor adherence. 
 
Part D consists of the appendices for the previous three sections. It includes a study approval letter 
form the University of Cape Town’s Human Research Ethics Committee; copies of the measurement tools 
used in the study in English and isiXhosa; consent forms; additional inserts, including an expanded table of 
Cronbach’s alphas and a correlation matrix; and journal submission guidelines. 
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 1 
Adherence in HIV-Positive Women Entering Antenatal Care 
on Antiretroviral Therapy: A Cross-sectional Study 
 
 
I. Summary 
The Western Cape government has implemented Option B+ as the standard of care at all public 
sector clinics1. Option B+ dictates that once an HIV-positive woman presents for antenatal care at a 
government clinic, she initiates antiretroviral therapy (ART) for life. This is a major change from previous 
protocol, where women were only put on ART temporarily during pregnancy (Option A) or placed on lifelong 
treatment when their CD4 count dropped below 350 cells/µl. Option B+ eliminates the gaps between 
pregnancies and illness where a woman would not be on ART, leading to continuous care1. This will result in 
a growing population of women of child-bearing age who continue on ART and are expected to maintain 
adherence to their medication. 
 However, clinical studies of ART adherence have historically enrolled mostly male participants2, and 
findings are often not reported by participants' sex2,3. It is known that barriers to adherence vary between the 
genders, and that women have been described as having lower levels of adherence than men3,4. Further, 
very little is known about the patterns of adherence among women conceiving on ART5, who are a newly 
emerging population6. Pregnancy involves an additional set of complications for women that could further 
impede adherence 6. These barriers might be different for long time users of ART, who are familiar and 
possibly more comfortable taking their medication than women who initiate ART for the first time during their 
pregnancy, however more study is needed into this new population.  
We intend to address key questions surrounding this understudied population regarding the 
prevalence of poor adherence and significant factors associated with this outcome by conducting a 
secondary analysis of data collected during the Maternal and Child Health Antiretroviral Treatment (MCH-
ART) study from a population of HIV-positive pregnant women who initiated ART prior to their current 
pregnancy and have presented at a midwife obstetric unit (MOU) in Gugulethu, Western Cape.  
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II. Introduction 
2.1 Background 
In 2013, the World Health Organisation (WHO) released guidelines that recommended all HIV-
positive pregnant or breastfeeding women start antiretrovirals, and provided an option for these women to 
continue on lifelong treatment7. This recommendation was based on a modified programme adopted by the 
Ministry of Health in Malawi,8 which came to be known as Option B+.  
Early research on this new treatment protocol has shown positive outcomes. Modelled maternal 
outcomes were shown to be better, with increased maternal life expectancy8. It was posited that these 
women benefitted from uninterrupted treatment between pregnancies, simplified drug regimens, and not 
waiting for a low CD4 count to start treatment8.  
The Western Cape Department of Health adopted Option B+ as a treatment protocol for HIV-positive 
pregnant women in the public sector in July 20131. When an HIV-positive woman presents at a public 
antenatal clinic, she has a viral load taken if it was not done in the past three months. If possible, she is 
switched to a fixed dose combination antiretroviral treatment; otherwise she is left on her current regimen. 
Adherence is checked throughout the pregnancy and continues to be monitored into the post-partum period, 
during which treatment continues 1. Keeping these sexually active women of childbearing age on ART has 
led to an increasing population of HIV-positive women conceiving while established on treatment.  
For South Africa, how well this growing group of long term ART users implement their medication if 
they become pregnant is of major concern. Adherence to ART is important during the antenatal period. 
Consistently taking antiretrovirals as prescribed has been shown to be the critical determinant in health 
outcomes for HIV-positive individuals4. Barron et al. found that about 70% of maternal deaths in South Africa 
in 2011 were associated with HIV infection9. Adherence to ART greater than 95% can lead to viral 
suppression, which helps maintain health and avoid progression to AIDS4.  
Not only does satisfactory adherence prevent maternal illness, but it will also prevent transmission of 
HIV to unborn children5. In 2007 about 300,000 babies were born exposed to HIV in South Africa10. Despite 
this high burden, mothers can protect their infants from exposure to the virus by simply taking their ART. 
Research from the European Collaborative Study found that every additional week of ART taken reduced the 
risk of vertical transmission of HIV to the foetus11. This protection extends into the postnatal period, as 
women who maintain a suppressed viral load are less likely to infect their baby with HIV via breastfeeding12. 
In short, satisfactory adherence to ART is crucial to maintaining the health of both mother and newborn.  
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There is also evidence to suggest that conceiving on ART provides improved outcomes for the 
infant. The European Collaborative Study found that the best paediatric outcomes were among women who 
conceived while established on ART11,13,14. They also showed that women who started ART before 
conception were more likely to achieve undetectable viral loads over the course of the study compared to 
those who started treatment after13. This low or undetectable maternal viral load is critical in the prevention of 
mother to child transmission (PMTCT) in utero15. These findings were supported by an additional study that 
found fewer cases of mother to child transmission (MTCT) in women who conceived on ART when 
compared to women who only initiated treatment during pregnancy14.  
Despite these positive outcomes, adherence to treatment is difficult as pregnant women have unique 
barriers to complete compliance. Women are already more likely to have worse adherence than men and 
more likely to be lost to follow-up in studies of adherence3,4. Pregnancy brings new obstacles6, such as 
anxiety about the infant's HIV status; travel to the family home to stay after delivery; and inadequate partner 
support, especially among women who have not disclosed their status to their partners10. Additionally, fear of 
the potential harm ART could have on their unborn infant can cause women to become non-adherent during 
pregnancy11.  These factors can make it near impossible for people who are otherwise willing and able to 
adhere to their medication to do so. A systematic review of antiretroviral adherence among pregnant women 
from all around the world found mean adherence of 50% to 61% for women during the prenatal period5. This 
further declined to 34 to 64% in the postpartum period. 
Although there is poor reported adherence among this important group, there is a paucity of 
research into ART adherence among women, and even fewer articles written about adherence in pregnant 
women5. Clinical antiretroviral trials since 2000 have only recruited on average about 20% women for their 
study populations, making any insights that could be drawn from this small participant group too 
underpowered to be conclusive2. With respect to those who have initiated ART under Option B+, there is a 
call for more research into adherence and retention to treatment among this population7. The WHO's goal of 
elimination of MTCT by 20154 relies on ART adherence throughout the PMTCT cascade and bolstering 
support for women to ensure they are able to take their medication as prescribed.  
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2.2 Objectives 
Primary Objective: 
1. To describe the prevalence and determinants of adherence to antiretroviral treatment among HIV-positive 
pregnant women who initiated treatment before their current pregnancy and who presented for antenatal 
care at a Gugulethu MOU. 
Key research question: How common is poor adherence to ART among HIV-positive pregnant women, and 
what are the significant causal factors for poor adherence among this population? 
 
Secondary Objectives: 
1. To describe the study population, looking at the distribution of socio-demographic variables and other risk 
factors measured. 
Key research question: What are the prevalence and patterns of socio-demographic variables and measured 
risk factors in the study population? Do these patterns differ between participants that report satisfactory 
adherence and those who report unsatisfactory adherence? 
2. To explore the agreement and validity of scale measures used to quantify study variables in this study. 
Key research question: How valid are the tools used to measure these variables in the study? 
3. To describe the relationships between the numerous self-reported measures of ART adherence taken in 
this study in order to select a valid outcome measure of adherence. 
Key research question: How consistent and agreeable are the variables using different measures of self-
reported adherence? 
 
III. Methods 
3.1 Study design 
The MCH-ART study is unique in that it employs three phases on different sub-sections of the same 
participant population to answer different study objectives. Phases 2 is a prospective cohort that follows 
pregnant women eligible for ART initiation through three clinic visits into the postpartum period. Phase 3 is a 
randomized control trial with two arms comparing ART delivery methods for HIV-positive women who have 
recently delivered. Phase 1, the phase from which these study data and analysis will be derived, used a 
cross-sectional survey at an MOU in Gugulethu, Western Cape. Participants were sampled consecutively for 
this phase of the study, and enrolment lasted from April 2013 through May 2014.  
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3.2 Population and sampling 
Population 
For this analysis, women were considered for inclusion if they were over 18 years of age, pregnant 
and HIV-infected. Women needed to have started ART prior to their current pregnancy, which was defined 
as being on ART for at least four months prior to enrolment. HIV status was confirmed by either two positive 
rapid tests or supporting documentation brought in by participants. Either an ultrasound, urine test or clinical 
assessment was used to confirm current pregnancy.  
Participants were excluded if they were not currently pregnant or if they had a medical, physical or 
social condition that would preclude them from properly consenting or participating in the study. These 
conditions included, but were not limited to, denial of HIV status and refusal to take ART. 
 
Method of sampling 
Consecutive patients were sampled for this phase of the study. At their first visit to the MOU, women 
were briefly informed by unit staff of the MCH-ART study and those who expressed interest in participating 
were introduced to study staff. Prospective participants were then given more information about MCH-ART 
by study workers. Informed consent (see protocol Appendix A) was attained by study workers from women 
who met inclusion criteria and who expressed a desire to participate in Phase 1 of the study only.  
 
Sample size 
Using this procedure, 1,544 women were recruited for this phase of the MCH-ART study.  Of these 
women, 535 were reported having been on treatment for at least four months. This was considered long 
enough to have been able to conceive on ART. Further analysis of treatment history taken from data 
abstraction of medical records, 33 participants were dropped from the data set as their start date for 
treatment was less than four months before their MOU visit date, meaning that they were not considered to 
have been established on ART prior to their current pregnancy. A total of 486 participants met all the criteria 
for inclusion and had no missing data.  
 
3.3 Measurements 
After consent was given, participants completed a 20-minute series of questionnaires that gathered 
information on demographics and various risk factors for ART non-adherence (see protocol Appendices B-I). 
The questionnaires were administered in either English or isiXhosa to participants by study staff.  
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Instruments 
The following tools were used in Phase 1 of the MCH-ART study (see protocol Appendices B-I): 
1. Demographics and Medical History  
2. HIV Treatment Knowledge Inventory16 (adapted) 
3. HIV/AIDs Knowledge Inventory17 (adapted) 
4. Adherence Self-Efficacy Scale18  
5. Beliefs about Medications Questionnaire19  
6. London Measure of Unplanned Pregnancy20 
7. Family Planning Use/Intentions  
8. Maternal Adherence Questionnaire21  
 
Among the questionnaires put to study participants were those designed by investigators for use in 
the MCH-ART study. These included questionnaires on demographics, socio-economic status and medical 
history; and family planning and intention to become pregnant. The other measures used in the study were 
sourced from published peer-reviewed articles. These measured participants' knowledge of HIV and HIV 
treatment; ART medication beliefs; pregnancy intentions; self-efficacy and confidence in taking medication; 
and ART adherence.  
After completion of the questionnaires, 5 ml of blood was collected to assess participants' viral loads. 
Specimens were batch tested using an Abbott Molecular RealTime HIV-1 assay (Abbott Molecular, Illinois, 
USA).  
 
Outcome of Interest and Independent Variable 
There is no agreed upon method of measuring adherence to ART used in pharmaceutical or 
epidemiological studies22. Neither is there an agreed upon percentage of medication a participant must take 
as advised to denote “good adherence”23. The best adherence can be defined as is “the level to which 
patients follow medical advice or treatment plans such as taking medications, keeping medical appointments 
and maintaining lifestyle changes”5. 
Phase 1 of the MCH-ART study uses a few different self-reported measures of participants' 
adherence to their medication (see Protocol Appendix I): 
1. Self-reported number of missed doses of antiretroviral medication in the past 30 days 
2. Self-reported Likert scale of adherence to antiretroviral medication in the past 30 days 
3. Self-reported Likert scale of adherence to antiretroviral medication since initiation of treatment 
 
 After careful consideration, it was determined that a binary variable separating participants into those 
who missed no doses of ART in the past 30 days and those who missed one or more doses should be the 
outcome of interest. 
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Table 1: List and definition of variables that will be examined for analysis of Phase 1 data: 
Variable Definition Scale 
Demographics   
Age (years) Participant age Numerical (continuous) 
SES Category Composite score derived from participant employment status; 
level of education attained; number of assets; housing type; and 
whether or not participant receives any social grants. This raw 
score was then categorised into low, middle and high.  
Categorical (ordinal) 
Education Level of school participant had completed Numerical (discrete) 
Employment Whether participant was employed Categorical (binary) 
ART Duration Number of months participant has been on treatment Numerical (continuous) 
CD4 Count Taken from participants' raw CD4 counts and made into three 
categories: <350; 350-499; and 500 and over 
Categorical (ordinal) 
Viral Load Taken from participants' raw viral load and made into two 
categories: Detectable (>50) and undetectable (≤50) 
Categorical (binary) 
Intrapersonal    
Self-efficacy Composite score taken from participants' responses measuring 
their self-efficacy and confidence in taking their medication and 
following guidelines. Taken from a 15-item scale, with responses 
ranging from “Not at all confident” (1) to “Very confident” (5). The 
higher the score, the more desirable responses given. 
Numerical (discrete) 
Medication 
beliefs 
Composite score taken from participants' responses measuring 
their confidence and perceptions towards their medication. 
Taken from 7-item scale, with participants agreeing, disagreeing 
or saying they did not know. The higher the composite score, the 
more responses the participant gave that demonstrated a 
positive belief in their ART.  
Numerical (discrete) 
Maternal 
Adherence  
Composite score taken from participant's responses ranking 
their adherence to their medication. Drawn from four scale 
items, the higher the composite score, the better the self-
reported adherence.  
Numerical (discrete) 
London Measure 
of Unplanned 
Pregnancy  
Taken from the questionnaire with the same name, this 
measures the intentionality of the participants' current 
pregnancies. The higher the raw composite score the more 
intentional the pregnancy 
Numerical (discrete) 
HIV Treatment 
Knowledge 
Composite score taken from participant's responding either 
“True,” “False,” or “I don't know” to statements concerning 
antiretrovirals. A point was given for a correct response, and no 
points for an incorrect or “I don't know.” The higher the 
composite score, the more correct responses given 
Numerical (discrete) 
HIV/Aids 
Knowledge 
Inventory 
Composite score taken from participant's responding either 
“True,” “False,” or “I don't know” to statements concerning the 
transmission or science of HIV/Aids. A point was given for a 
correct response, and no points for an incorrect or “I don't know.” 
The higher the composite score, the more correct responses 
given 
Numerical (discrete) 
Interpersonal   
Disclosure 
status 
Whether or not a participant has disclosed their status to another 
person 
Categorical (binary) 
Male partner 
disclosure 
Whether or not a participant has disclosed their status to their 
current male partner 
Categorical (binary) 
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3.4 Limitations 
Selection Bias 
This cross-sectional survey was conducted on a group of HIV-positive women established on ART 
and attending a MOU at their fourth month of pregnancy. This sampling frame excludes those HIV-positive 
women who do not seek antenatal care or who book for care later in the pregnancy. This group of women 
might have a different level of adherence and separate risk factors for poor adherence than the women who 
received timely antenatal care and were sampled. The differences between these groups cannot be 
assessed, as data on HIV-positive women not at the antenatal clinic could not be collected by virtue of them 
not being present to be sampled in this cross-sectional study. Keeping this in consideration, the study 
population must be carefully defined in the analysis and subsequent reporting of the study's findings.  
 
Information Bias 
Not all participants sampled for this analysis have complete data. Where a participant is missing data 
for a questionnaire, they will be dropped from the analysis. However, these participants will be compared 
against the rest of the study population to ensure that they are not different with regard to the frequency of 
the outcome or other major risk factors.  
The outcome measure used in this analysis will be a self-report of adherence. As with all self-
reported measures, there is a potential for bias here. Self-reported measures of adherence are notoriously 
less reliable than other objective measures, such as refills or claims-based measures24. However general 
correlation between self-reported adherence and MEMs cap, an objective measure, has been shown25. To 
show some internal validity, the selected outcome measure will be compared against other self-reported 
adherence measures used in the survey to assess their correlation.  
 
Confounding 
One of the limitations of this analysis is that during Phase 1, data were not collected on some 
potential risk factors identified in a review of the literature. We will not be able to adjust for the effect of 
barriers to adherence previously identified through a review of the literature, such as alcohol consumption26, 
depression16,26, and experiencing medication side-effects24. As such, there is potential for confounding that 
cannot be adjusted for.  
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IV. Analysis plan 
All quantitative analysis will be conducted using Stata Version 11.0 (Stata Corporation, College 
Station, Texas).  
 
Secondary Objective 1: 
Proportions of participants' demographics and reported risk factors will be calculated. The 
distribution of these variables in the population will be examined with special attention given to those factors 
identified in the literature as potential risk factors. This background information on demographics and self-
reported adherence measures will be tabulated to describe the population.  
Risk factors identified during a review of the literature will be compared between participants who 
missed no doses and those who missed one or more doses in the last 30 days, to contrast between outcome 
groups. Chi-squared tests or Fisher's Exact will be used for categorical variables and two-sample t-tests or 
rank-sum tests for numerical variables. All tests will be analysed using a cut-off of 95% for the significance 
level.  
 
Secondary Objective 2: 
Six separate tools were used to measure risk factors in this population. The “HIV Treatment 
Knowledge” and “HIV/AIDS Knowledge Inventory” tools used true and false questions to assess study 
participant's knowledge of their disease and treatment, also giving an option for “I don't know.” Composite 
scores will be generated for all participants for each of these measures, giving a point for a correct response 
and no points for an incorrect response or “I don't know.” 
The other four tools used Likert scales to assess how participants rated their self-efficacy; their belief 
in their medications; their adherence to their medication; and the intentionality of their pregnancy. Composite 
scores will be generated for these tools as well, with higher points given for more favourable responses (i.e. 
a response that indicated greater confidence in medication keeping a person healthy would receive a six).  
For all of these scales, a Cronbach's alpha will be calculated to assess the performance of these 
tools on this population. Any alpha above 0.7 will be considered acceptable, and will be considered in 
looking at the validity of the composite scores for participants and their inclusion in the model building 
process.  
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Secondary Objective 3: 
Participants will be split into two groups based on whether they self-reported missing no doses in the 
past 30 days, or missing one or more doses. Other self-reported adherence measures, such as self-rating of 
adherence since initiation and in the last 30 days, will also be compared between these two groups to 
assess correlation and consistency between the measures of adherence. To further explore and validate the 
chosen outcome measure, participant's viral loads will be compared to their self-reported missed dosage. 
This will be done using chi-squared tests, comparing the missed dose categories to detectable and 
undetectable viral load. All tests will be analysed at 95% level of significance.  
 
Primary Objective: 
Finally, a logistic regression model will be constructed using significant variables identified in the 
bivariate analysis. The variables will be fit in three stages, separating the risk factors into socio-demographic, 
intrapersonal and interpersonal risk factors, a method of organising these variables that evolved from ideas 
in Clouse et al.6.  
A table will be constructed that displays these stages of model building that reports odd ratios and 
95% confidence intervals to show significance. Panel 1 will show empty models for each of the significant 
variables, exploring their unadjusted relationship to the outcome. Panel 2 will adjust for hypothesised 
associated demographic variables and individual risk factors separately to give adjusted odds ratios. Panel 3 
will start to build the final model, adjusting for associated demographic variables and significant intrapersonal 
variables together. The final step will be in Panel 4, which will fit both significant intrapersonal and 
interpersonal factors into a logistic regression model.  
 
V. Ethics 
Ethical approval for the MCH-ART study was attained from University of Cape Town's Faculty of 
Health Scienes Human Research Ethics Committee (UCT-HREC) and the Columbia University Medical 
Center Institutional Review Board (CUMC-IRB) (see protocol Appendix J). The two boards reviewed the 
study protocol, informed consents, questionnaires, procedures and other associated documents before 
giving their final approval. Both organisations also follow up with the MCH-ART study on an annual basis to 
review its progress.  
This analysis of already-collected data from the MCH-ART study does not present any potential risks 
to the women who participated in this study. All of the data that will be analysed have been anonymised, and 
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the only identifying marker for study participants is the patient ID they were assigned at enrolment. The 
graduate student undertaking the analysis will not have direct access to participant files or medical records 
that have been abstracted. In the event that the graduate student needs access to the original forms to 
check a discrepant response, the graduate student will be supervised by the MCH-ART study manager 
and/or the student's advisor.  
 
VI. Stakeholders, reporting and implementation 
Upon completion of analysis and revision, an article from the findings of this secondary analysis will 
be published in a peer-reviewed journal. Through publishing, the findings of this study will be made public 
and will help to inform academics and medical practitioners working with similar patient populations. We 
believe that medical practitioners, public health researchers and policymakers involved in the areas of 
PMTCT and maternal health will be interested in the findings from this analysis. It is hoped that by sharing 
the findings of the analysis of Phase 1 data from the MCH-ART study, greater light can be shed onto the 
barriers of adherence among HIV-positive pregnant women currently on ART, an understudied and yet 
incredibly important group. 
 
VII. Logistics 
As this is a secondary analysis of data that has already been collected from a study that has already 
received approval from CUMC-IRB and UCT-HREC, very little remains in the way of logistics. All that 
remains for the graduate to do is to finalise and write a review of the literature, to conduct the outlined 
analysis of the data and to write-up the final article for submission in her thesis.  
 
 
 
 
 
 
 
 
 
 12 
VIII. References 
1. Government of the Western Cape. PMTCT Clinical Guidelines Update. 2013 p. 1–29. 
2. Anderson J. Women and HIV: motherhood and more. Current Opinion in Infectious Disease. 
2012;25(1):58–65. 
3. Puskas CM, Forrest JI, Parashar S, Salters K a, Cescon AM, Kaida A, et al. Women and vulnerability to 
HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. 
Current HIV/AIDS Report. 2011;8(4):277–87. 
4. Nachega JB, Uthman O a, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to 
antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income 
countries: a systematic review and meta-analysis. AIDS. 2012;26(16):2039–52. 
5. Vitalis D. Factors affecting antiretroviral therapy adherence among HIV-positive pregnant and postpartum 
women: an adapted systematic review. International Journal of STDs and AIDS. 2013;24(427):427–
32. 
6. Clouse K, Pettifor A. “What they wanted was to give birth; nothing else”: Barriers to retention in Option B+ 
HIV care among postpartum women in South Africa. Journal of Acquired Immune Deficiency 
Syndromes. 2014;67(1):e12–e18 
7. Shaffer N, Abrams EJ, Becquet R. Option B+ for prevention of mother-to-child transmission of HIV in 
resource-constrained settings: great promise but some early caution. AIDS. 2014;28(4):599–601. 
8. Ahmed S, Kim MH, Abrams EJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and 
breastfeeding women: a review of the evidence for the Option B+ approach. Current Opinion in HIV 
and AIDS. 2013;8(5):474–89. 
9. Barron P, Pillay Y, Doherty T, Sherman G, Jackson D, Bhardwaj S, et al. Eliminating mother-to-child HIV 
transmission in South Africa. Bulletin of the World Health Organisation. 2013 Jan 1;91(1):70–4. 
10. Peltzer K, Mlambo M, Phaswana-mafuya N, Ladzani R. Determinants of adherence to a single-dose 
nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in 
South Africa. Acta Paediatrica. 2010;99:699–704. 
11. Stinson K, Myer L. Barriers to initiating antiretroviral therapy during pregnancy": a qualitative study of 
women attending services in Cape Town , South Africa Barriers to initiating antiretroviral therapy 
during pregnancy: a qualitative. African Journal of AIDS Research. 2012;11(1):65–73. 
12. Chi BH, Stringer JS a, Moodley D. Antiretroviral drug regimens to prevent mother-to-child transmission of 
HIV: a review of scientific, program, and policy advances for sub-Saharan Africa. Current HIV/AIDS 
Reports. 2013;10(2):124–33. 
13. European Collaborative Study. Mother-to-Child Transmission in of HIV Infection the Era of Highly Active 
Antiretroviral Therapy. Clinical Infectious Diseases. 2005;40(3):458–65. 
14. Hoffman R, Black V, Technau K, van der Merwe KJ, Currier J, Coovadia A, et al. Effects of Highly Active 
Antiretroviral Therapy Duration and Regimen on Risk for Mother-to-Child Transmission of HIV in 
Johannesburg, South Africa. Journal of Acquired Immune Deficiency Syndromes. 2010;54(1):35–41. 
15. European Collaborative Study. Factors associated with HIV RNA levels in pregnant women on non-
suppressive HAART at conception. Antiviral Therapy. 2010;15(1):41–9. 
16. Wagner GJ, Remien RH, Carballo-Diéguez A, Dolezal C. Correlates of adherence to combination 
antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care. 
2002;14(1):105–9. 
17. Kalichman S, Simbayi L. HIV testing attitudes, AIDS stigma, and voluntary HIV counselling and testing in 
a black township in Cape Town, South Africa. Sexually Transmitted Infections. 2003;79:442–8. 
18. Chesney MA, Ickovis JR, Chambers DB. Self-reported adherence to antiretroviral medications among  
participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12(3):255-266.  
 
19. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and 
evaluation of a new method for assessing the cognitive representation of medication. Psychology and 
Health. 1999;14(1):1–24. 
 
 13 
20. Barrett G, Smith SC, Wellings K. Conceptualisation, development, and evaluation of a measure of 
unplanned pregnancy. Journal of Epidemiology and Community Health. 2004;58(5):426–33. 
21. Wilson IB, Fowler, Jr. FJ, Consenza CA, Michaud J et al. Cognitive and Field Testing of a New Set of 
Medication Adherence Self-Report Items for HIV Care. AIDS and Behavior. 2014;18(12):2349-2358. 
22. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to Highly Active 
Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African 
Adults. Journal of Acquired Immune Deficiency Syndromes. 2006;43(1):78–84. 
23. Mills EJ, Nachega JB, Buchan I, Orbinski J. Adherence to Antiretroviral Therapy in Sub-Saharan Africa 
and North America. Journal of the American Medical Association. 2006;296(6):679–90. 
24. Blaschke T. Scalable Adherence Interventions. HIV Research for Prevention. Cape Town; 2014. 
25. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, et al. Multiple validated 
measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a 
resource-limited setting. Journal of Acquired Immune Deficiency Syndromes. 2004;36(5):1100–2. 
26. Mellins C a, Chu C, Malee K, Allison S, Smith R, Harris L, et al. Adherence to antiretroviral treatment 
among pregnant and postpartum HIV-infected women. AIDS Care. 2008;20(8):958–68. 
 
 
 Part B:  
 
Literature Review 
 1 
 
I. Introduction 
 
Adherence to medication is a complicated and nuanced issue. What constitutes adequate adherence 
to any one treatment differs with the medication studied, depending on the pharmacology; the population 
being studied; the number of pills skipped or taken incorrectly over a specific time period; how long that time 
period is and how representative that time period is of that person's life1,2. 
These complications ring especially true with regards to the study of antiretroviral therapy (ART) for 
the management of HIV3. There is no agreed upon method for measuring ART adherence, or even what 
percentage of pills a participant must take correctly to be considered adherent4. Generally, the percentage of 
ART taken that is considered good adherence ranges from 80% to the strict 100%5, however the study 
reporting that range found no significant difference in survival for patients who reported between 80-99% and 
total adherence. For ART patients, adherence of 95% or better is required to achieve viral suppression1. This 
means not missing more than one pill a month6. 
Despite these differences, adherence to ART remains the determining factor in HIV treatment 
outcomes6. ART is crucial in delaying illness and maintaining health, as poor adherence significantly 
increases the risk of death in HIV-positive individuals. This is due to the close relationship between ART 
implementation and a high viral load being associated with disease progression and adverse health 
outcomes1,7. A suppressed viral load leads to better long term health outcomes and longer life in this 
population1,4,5.  
Additionally, good adherence can make transmission to another person more difficult through a 
suppressed viral load1,6. This benefit is critical for neonate health7. A low viral load helps in the prevention of 
mother to child transmission (PMTCT), allowing children born to HIV-positive mothers to avoid infection in 
utero and in the postnatal period8–10. This is of major importance to South Africa, where nearly one out of 
every three pregnant women is HIV-positive11. It is a necessity to public health in South Africa to better study 
adherence and characterise the barriers pregnant women face in taking their medication.  
There is a gap in the knowledge when it comes to women's adherence to ART, especially among the 
growing population of HIV-positive pregnant women who have been established on ART before presenting 
for antenatal care1. Though this is an established population of HIV-positive women in more developed 
areas, like Western Europe12, the implementation of treatment protocols like Option B+ in less developed 
countries13 will result in new subsets of this group now beginning to emerge. A 2014 study of HIV-positive 
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postpartum women in Johannesburg found that 30% of those interviewed had initiated ART prior to 
pregnancy, with a median duration of 2.6 years14.  
The complexity of adherence and the lack of agreement within the scientific community as to what 
constitutes being “adherent”1,5 leave room for research into ART adherence and exploration of differing 
definitions of that outcome. The aim of this literature review is to identify current issues in adherence 
research in pregnant women, with special attention to studies that speak to the barriers faced by women who 
are long time users of ART. It will serve to highlight current issues in adherence research, such as the 
reliability of measures of adherence, differing definitions of good adherence and risk factors for poor 
adherence. This is to better inform the primary purpose of this thesis: To describe the prevalence and 
determinants of adherence to ART among HIV-positive pregnant women who initiated their treatment before 
their current pregnancy and who presented for antenatal care at a Gugulethu midwife obstetrics unit (MOU). 
 
1.1 Literature Search Strategy 
A review of the literature was conducted through Google Scholar and Pubmed for scholarly reviewed 
papers published up until December 2014. Search terms included the following terms in combination and 
alone: “adherence”, “pregnancy”, “ART”, “HAART”, “nevirapine”, “antiretroviral”, “conceive”, “initiate”, “South 
Africa”, “Cape Town”, “viral load”, “Option B+”, “HIV”, “PMTCT”, “European Collaborative Study”. Conference 
proceedings, book chapters and government policy handbooks were also included in this review, along with 
systematic reviews and meta-analyses.  
 
II. Background 
In 2013, the World Health Organization (WHO) released updated guidelines that recommended all 
HIV-positive and breastfeeding women initiate antiretrovirals and gave an additional option for women to 
continue lifelong treatment after giving birth15. This plan, which came to be known as Option B+, was quickly 
adopted by the Malawian government16. Modelling of maternal health outcomes were shown to be better 
under Option B+, with increased maternal life expectancy17. This same study also showed that women 
benefit from Option B+ by starting treatment earlier, having no treatment interruption between pregnancies 
and not waiting for a low CD4 count to start treatment for life17. They posited that simplifying treatment 
regimens and delivery would decrease transmission and improve retention outcomes among women.  
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Eliminating interruptions in ART for women who have already had a child will also benefit those who 
might go on to have an unplanned pregnancy. Studies have found a significant portion of pregnancies 
among HIV-positive women are in fact unintended12, with it estimated that just over half of pregnancies in 
HIV-positive European women are unplanned. This is important in South Africa, where unplanned pregnancy 
is common in some areas. In a cross-sectional survey of pregnant women in KwaZulu-Natal (KZN), 86% of 
participants said their pregnancies were unintended18. Extending ART coverage past the postpartum period 
means also extending coverage to the early days of these potential unplanned pregnancies, when the 
mother might not otherwise know she is pregnant and before she presents for antenatal care.  
However, the WHO has called for more research into adherence and retention in antiretrovirals on 
this new plan, over concerns with long-term retention on ART because of initiation happening much sooner 
for women and the acceptability of this change15. There also remain questions over the change in 
messaging, as women who were previously told to only come in for ART when feeling sick are now expected 
to initiate and maintain treatment for life regardless of whether they feel healthy15.  
 
III. Concepts and Definitions 
3.1 Outcome 
Measuring Adherence 
There is no gold standard measurement of adherence widely embraced by researchers3,4, and all 
measures come with their own drawbacks. With measurements of adherence, researchers must weigh 
reliability, richness of sampling and feasibility2. Different study purposes require assessment tools with 
different sensitivity3 to adequately quantify adherence. For self-reported measures, phrasing is also an issue. 
Changes in how a question is presented, such as ranking adherence on a scale of 1 to 10 compared to 
assigning an adjective to describe their adherence can greatly affect responses19.  
In his presentation at the 2014 HIV Research for Prevention conference, Terrence Blaschke singled 
out recall questionnaires of adherence as being unreliable and providing sparse information for clinical trials 
of medication2. Generally, self-report and patient diaries, though cost-effective and quick, are notorious for 
recall bias and having low reliability6. Electronic monitoring systems and biological measures can provide 
more reliable measures, but are often unrealistic for most studies2. Self-reporting can exaggerate the 
incidence of good adherence, showing higher levels of adherence to ART amongst HIV-positive participants 
when compared to pharmacy refills or “claims-based measures”7. In contrast, Oyugi et al. found good 
agreement between patient self-report, pill counts and MEMSCaps20.  
 4 
Adherence in South Africa 
Low- and middle-income countries (LMICs), and even resource poor settings in more developed 
countries, can provide unique barriers to adherence. In South Africa specifically, antiretroviral stock outs, 
long lines at clinics and issues with transport can frustrate patients and prevent them from accessing their 
medication14. Qualitative interviews of South African HIV-positive participants brought to the fore people's 
fear of status disclosure by clinic workers, or being deduced by community members. Clouse et al. found 
that women who continued to seek medical care after giving birth to their infants were viewed with suspicion 
by their community14. This perceived stigma caused some women to skip clinic visits and become non-
adherent to their medication14.  
But studies of adherence to ART in LMICs have shown promising results. HIV-positive people from 
Africa had a higher percentage of adherent patients compared to those in North America according to a 
meta-analysis from Mills et al.5. In another meta-analysis, 77% of African patients took over 80% of their 
medication correctly, meeting the study's definition of good adherence6. Nachega et al. did bring up issues of 
over reporting of adherence in studies conducted in Africa, as these studies tend to have shorter follow-up 
time and more self-reported outcomes than compared to studies in more developed regions4.  
Poor access to resources does not necessarily mean health services are unavailable. Boyles et al. 
showed that successful service delivery is possible in resource-constrained settings21, meaning that 
antiretrovirals should be available in overstretched community clinics. Supporting this, in a 2004 Soweto 
study of antiretroviral adherence in a resource-constrained setting, 88% of participants reported greater than 
95% adherence for the previous month22. A systematic review and meta-analysis7 had South African studies 
reporting 60% to 86% of their participants reporting adequate adherence, though studies differed in definition 
of adherence and methods.  
 
Adherence in Women 
The story of ART adherence in women is a complicated one. From the start, women are 
underrepresented in clinical trials of ART among HIV-positive people, as drug trials of antiretrovirals since 
2000 have recruited about 20% women on average23. There are some studies, like Nachega et al., which 
found that women were more likely than men to have adherence higher than or equal to 80% amongst South 
Africans4. However, women generally have poorer adherence than do their male counterparts7. Heterosexual 
women had the lowest rates of adherence in a study of recalled medication adherence from the previous 
three days among gay men, heterosexual men and heterosexual women in the United States24. Only one 
woman reported perfect adherence compared to 15 gay men who reported perfect adherence. 
 5 
Women fare worse with regards to adherence for a variety of reasons. A number of studies suggest 
that, because women are more likely to place greater importance on their relationship with others and their 
standing within their community, their adherence suffers because of issues around disclosure and self-
efficacy23,25. Anderson et al. found that women’s experiences with depression, stress, stigmatization and the 
importance placed on social relationships affect adherence, making it generally less than that of men23. A 
study of pregnant women in Western Europe found that participants with at least two children already had 
poorer adherence to ART than those with no previous children26. This could indicate challenges women face 
caring for their families while maintaining adherence to medication26. 
 
Adherence during Pregnancy 
The literature shows that pregnant women have an even harder time remaining on treatment. A 
systematic review of antiretroviral adherence among pregnant women from all around the world found 
average adherence of 50% to 61% for women during the prenatal period1. This study went on to find that 
adherence declined to 34% to 64% in the postpartum period. A South African study showed that about half 
of women dropped out of HIV care after delivery14. Wang et al. found that women were more likely than men 
to be lost to follow-up six months after initiating ART11. In this study, pregnancy status, along with gender, 
were the only factors significantly associated with being lost to follow-up at six months. A cohort study in the 
Eastern Cape found that women who initiated ART for the first time during pregnancy were over three times 
more likely to be lost to follow-up at the end of the study period than those who did not initiate ART in 
pregnancy21.  
There are unique problems for HIV-positive women who conceive their infants after having already 
initiated ART, as they not only have to navigate issues related to their pregnancy, but may also have to deal 
with changes in ART regimen and side-effects from their medication1. But very little study has been done on 
this group. Some studies have been conducted on long term ART users in Europe8, however there is a 
paucity of information on adherence in pregnant women in developing countries1. The barriers to adherence 
in this population have not yet been described in a study, leaving an important niche for future research.  
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3.2 Risk Factors 
The list of barriers to adherence for pregnant women is long, and includes factors such as lack of 
partner support; anxiety about their infant's HIV status; and little motivation to adhere to lifelong medication 
after a healthy delivery14,27. However, this literature review will only focus on those issues addressed in 
Phase I of the MCH-ART study, leading to the omission of some important risk factors identified in other 
studies of antenatal ART adherence. For this review, risk factors were organised into three separate 
categories:  socio-demographic, interpersonal and intrapersonal14.  
 
Socio-demographic factors 
Age 
A number of demographic factors come into play when looking at adherence among HIV-positive 
women. Young age was found to be a barrier to adherence in a systematic review of pregnancy ART 
adherence studies, and being an older mother was shown to be more likely to contribute to good 
adherence1. A literature review found reduced adherence was associated with young age in women25. 
Young age has also been linked to post-partum loss to follow-up10.  
 
Socio-economic Status 
Financial issues have also been shown to be a barrier to adherence1. Qualitative studies profiled by 
Vitalis have highlighted the high cost of transportation, widespread poverty and financial dependence on a 
partner as barriers to adherance1. These are costs that someone of low socio-economic status (SES) would 
not be able to cope with14,28. Interviews with women in KZN identified lack of food and finances as a barrier 
to adherence29. Some women reported not disclosing their status to their partner, and thus hiding their ART, 
because they fear rejection30. For a woman in a relationship with a man where he is the financial provider, 
aside from the emotional trauma of possible rejection, a partner leaving them because of their HIV-status 
means the loss of financial stability30. Such dependency might make women less able to negotiate with their 
partner, impeding the use of ART or exclusive formula feeding of a newborn for PMTCT28.  
Though some studies have shown a positive link between SES and adherence, their relationship is 
not clear in the literature. Chesney et al. found that those who worked outside the home for money were 
actually more likely to report episodes of non-adherence in the previous two weeks31. Other studies have not 
found significant differences between good and poor adherers with regard to SES22.  
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Level of schooling 
Education is also a major demographic factor in studies of adherence. For example, more years of 
formal education were significantly associated with better medication adherence from the past three days24. 
A lower formal education has been identified as a barrier to adherence25. Similarly, mothers with no high 
school education were shown to be less adherent in the administration of Nevirapine to their babies 
postnatally compared to mothers with a high school education32 .  
 
Intrapersonal factors 
Medication Beliefs 
A woman's belief in her medication is a factor in how well she adheres to it1. Horne et al. found in 
their paper, where they introduced a new method of assessing medication belief, that the beliefs a person 
holds about their medication are likely to inform how they take it33. This determines if and when a patient 
takes their medication, if they take it as recommended by a health professional and whether it is continued33. 
Malcolm et al. found that the HIV positive patients with excellent adherence in Rhode Island who they 
sampled believed that 90-100% adherence was necessary to benefit from their medication34. HIV-positive 
participants with “greater perceived treatment efficacy,” “stronger belief that combination therapy is a 
significant treatment advancement,” and “greater hope that combination therapy would be effective” had 
better adherence24.  
 
HIV and ART Knowledge 
Similarly, a person's knowledge of their medication can be a very important influencing factor in their 
adherence to it. Wagner et al. found that greater knowledge of HIV treatment and understanding of the 
effects of poor adherence was associated with better ART adherence in a survey of serodiscordant 
couples24. A survey of ART patients in Rhode Island found that those who did not understand how their 
medication affected the virus had poorer adherence34. Misinformation about HIV prevention can be a huge 
barrier to accessing health services35, and can play into perceived stigma of HIV-positive people. Women 
need to understand the necessity for continued ART use because HIV-positive antenatal care attendees who 
do not otherwise feel ill are most at risk to be lost to care after delivery because they feel they have no 
incentive to continue lifelong treatment10.  
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Pregnancy Intention and Foetal Wellbeing 
Pregnancy intention is a complicated issue that involves the context under which the woman fell 
pregnant; the woman's stance on being pregnant; and the behaviour she undertook to either plan for or 
prevent the pregnancy36. Quantifying these ideas into a single pregnancy intention for participants helps 
researchers to conceptualise participants' attitudes towards their pregnancy without reducing these 
intentions to a couple of categories. Pregnancy intention could further characterise a woman's preparation 
for her unborn child, such as taking antenatal supplements36, and might speak to her concern for her unborn 
child's health and dedication to taking ART for PMTCT.  
A 2008 study found that women adhered better during their pregnancy than at a 6-month check-up27. 
Of these women who reported better adherence during pregnancy, 90% said they did so because of concern 
for their baby's health. Of these women who cited foetal well being as their primary reason for adherence, 
only 18% reported complete adherence postnatally27. Qualitative interviews at Cape Town public-sector 
primary care clinics and referral hospitals offering services to pregnant women, including ART services, 
showed that women adhered to ART in pregnancy to protect their children10. Concern for their child was 
found to be a major facilitator of adherence among HIV-infected pregnant women1.  
Inversely, concern for the foetus and its safety can also be major barriers to ART adherence as 
women's poor adherence comes from their need to protect their children from the perceived harm of 
medication1. Women put their children's health before their own after birth, sometimes sacrificing good 
adherence to care for their newborns10. In a survey by Clouse et al., 29.2% of women cited putting the 
baby's health before that of the mother as a reason why women were not adherent to ART14.  
 
Self-efficacy 
Self-efficacy is a person's belief in their own competence to achieve long term goals37. Self-efficacy 
has been shown to be an important factor for health behaviours for some chronic conditions38. It is especially 
important for those with HIV, as a new diagnosis can lead to feelings of “social isolation, despair and 
powerlessness”39. If these feelings persist, they can make treating a person’s HIV difficult. Because of this, a 
lack of self-efficacy has been identified as a barrier to adequate ART adherence in the literature1,40.  
Chesney et al. looked at correlates of non-adherence to ART in the previous two weeks in both men 
and women in the US31. They found that those who were less certain that they were capable of taking all or 
most of their medication as directed were more likely to report non-adherence31. Doherty et al. found low 
levels of reported self-efficacy in their cohort of HIV-positive South African mothers, and many participants 
also doubted their ability to care for their children39.  
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Interpersonal Factors 
Social support  
Support from family, friends and partners has been found to have a positive influence on adherence 
among pregnant women1. However, fear of losing this support by disclosing to friends and family can be 
equally as damaging to adherence. Interviews with women seeking antenatal care at public sector facilities 
around Cape Town showed fear of disclosure because of the threat of abandonment by their partner, and 
that this idea was common among women in relationships10. Promisingly, the study found that when the 
majority of these women did disclose to their partner, they had positive, supportive experiences. In a US 
study, patients who were open with family and friends about their HIV status were more likely to be excellent 
adherers to their medication than those who had not disclosed34.  
Women who have not disclosed often must make concerted efforts to make sure their family and 
neighbours do not discover their status. This can negatively impact adherence if they have to hide their 
medication or take it at times when people are not around41. Dahab et al. found that both patients and health-
care workers cited fear of stigma as a barrier to adherence and to modifying treatment adherence to suit 
their current circumstances40. This is dangerous, as having to hide medication can lead to taking it earlier or 
later than indicated and not achieving therapeutic levels for long enough to suppress viral load6. 
 
Partner involvement 
Partner involvement can be a determining factor in adherence for serodiscordant couples. A Stinson 
and Myer article showcased quotes from a series of interviews done with healthcare workers, in which one 
lamented that women bring in treatment partners for support in taking and/or beginning ART, but then 
“…'Usually the treatment buddy is a partner and then we lose them…. They don’t come back…. They don’t 
start because of a treatment buddy problem’”10. Another study found that lack of male involvement, lack of 
trust and confidentiality with healthcare workers and being a single woman were associated with mothers not 
taking nevirapine32. In this study, participants’ telling their partner about nevirapine was associated with 
maternal adherence, and father of the baby attending antenatal care visits was associated with HIV 
disclosure to male partner32.  
 
Stigmatization 
Building off this, fear of stigmatization is another societal barrier to disclosure, and as such is also a 
barrier to adherence. Turan and Nyblade described anticipated stigma, enacted stigma, perceptions of 
stigma and internalized stigma as all being potential negative psychosocial effects a women might 
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experience if she discloses41. In a later study, they found that stigma was a barrier to service uptake and 
adherence throughout the PMTCT cascade41. Women who experienced internalized stigmatization and 
thought that HIV-positive people should be ashamed, were far less likely to report having used antiretrovirals 
than women who did not carry this same stigmatization41. A study of healthcare workers revealed that they 
believed women who had difficulty accepting their HIV-positive status and displayed signs of internalized 
stigma, appeared less likely to initiate ART during pregnancy10. HIV-positive pregnant women have a harder 
time during pregnancy, as they might deal with an additional layer of stigma and judgment for getting 
pregnant and putting their unborn child at risk of HIV infection41. This is a complicated issue and plays into 
issues surrounding foetal well-being, and perceptions of poor motherhood.  
 
IV. Benefits of ART Adherence 
The benefits from having women, especially pregnant women, adhere to their treatment certainly 
outweigh the issues of getting them to take their medication properly. In South Africa in 2011, about 70% of 
maternal deaths were associated with HIV-infection42. Full adherence to treatment helps to keep women 
healthy by suppressing their viral load and decreasing their risk of developing illnesses associated with being 
HIV-positive7. Further benefit can be derived from the fact that taking ART during pregnancy greatly reduces 
the risk of a mother transmitting HIV to her child in utero. The European Collaborative Study found that every 
week of antenatal ART taken decreases the risk of vertical transmission of HIV to the foetus10.  However, the 
success and gains expected from expanding ART to lifelong coverage for all HIV-infected pregnant women 
depends on the proportion of those women who adhere properly to treatment and remain in care14. Because 
in South Africa 50% of women drop out of care after delivery14, finding a way to support ART use in the post-
partum period is crucial. Continued treatment into the post natal period leads to a continually suppressed 
viral load for the mother and therefore better health outcomes, and ART helps to prevent transmission of HIV 
to the infant through breastfeeding12. 
Conceiving while on ART leads to good health outcomes for the child. There are fewer instances of 
MTCT for women who conceived on ART when compared to women who initiated ART during pregnancy9. 
In fact, women who started ART before becoming pregnant were more likely to achieve undetectable viral 
loads over the course of a European Collaborative Study compared to pregnant women who started ART 
antenatally. That study also found that the infants with the best outcomes were born to mothers who started 
ART before their pregnancy8. Further driving the point home, Hoffman et al. observed no in utero 
transmissions among women who were on ART for more than 32 weeks before delivery9. 
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Improved adherence to ART could have huge impacts for HIV-positive women in South Africa. There 
is a high burden of HIV in this country, especially among pregnant women. About 1 out of every 3 pregnant 
women in South Africa are HIV-infected11. It was estimated that in 2007, 300,000 babies were born exposed 
to HIV in South Africa32. This is a huge number of children who have the potential to be born HIV-positive, 
and are therefore at risk for poorer health and early death than their HIV-negative counterparts.  
The benefits from widespread ART use could extend to the population level. If good adherence to 
ART was widely adopted amongst HIV-positive individuals, there would be a higher prevalence of 
suppressed viral loads and possibly fewer transmissions to negative individuals24. Though still in need of 
study, widespread good adherence could further lead to a lesser burden on the health care system and 
lower costs associated with HIV care. This is because better adherence could lead to fewer hospitalizations 
for conditions associated with untreated HIV6. There is also a danger from widespread non-adherence as 
well. Poor and intermittent adherence to ART can lead to drug-resistant strains of HIV, which might then be 
transmitted on to other people and lead to available and cheaper first-line HIV medications becoming 
ineffective1,6.  
 
V. Conclusion 
 There is no doubt that taking ART consistently and as prescribed can lead to viral suppression1, and 
that the longer a person is on treatment the better off they are9. Viral suppression can, in turn, lead to better 
health for an HIV-positive individual1,6,7. It can also impede the transmission of HIV to others24, including in 
utero transmission10, making it a critical component of an HIV-positive woman’s antenatal care14. If treatment 
is continued, this protection extends into the postnatal period12.  
 It is accepted that long time users of ART are an emerging population in South Africa14. With the 
adoption of Option B+, women of child-bearing age will be put on ART at their first pregnancy, continuing to 
take their medication for the rest of their life13. This is good news as pregnant women who are established 
ART patients have been shown to have better health outcomes for their infants8.  
 It is also known that there has been little dedicated study done on this growing population of 
women1. Without any insight into the barriers to adherence specific to this group, clinicians and researchers 
simply have to extrapolate from other groups with overlapping characteristics (i.e. long term users of ART; 
HIV-positive women initiating ART for the first time at pregnancy). This, however, does not accurately 
describe these women’s experiences and does not help health care providers to support adherence in this 
group.   
 12 
 My dissertation addresses this gap in the knowledge by focusing exclusively on HIV-positive women 
in a LMIC setting who conceived while already on ART. This analysis looks at a wide variety of factors 
associated with adherence in previous studies conducted in other populations to explore their associations to 
good adherence in this population. This research is a first step into characterising the experiences of this 
population in maintaining good adherence to ART, and will hopefully spur further interest in this area of 
study.  
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Background: With the adoption of Option B+ in the Western Cape, there is a growing population of women 
who are long-term users of antiretroviral therapy (ART). For some of these women, this results in conceiving 
on treatment as they no longer stop ART between pregnancies. However, limited research has been done 
into the barriers of adherence among this emerging group. 
Methods: From April 2013 through May 2014, cross-sectional data was collected from participants of the 
MCH-ART study who initiated ART prior to their pregnancy. A statistical analysis was then conducted, 
looking at correlates of good adherence.  
Results: Of the 486 women found to be established on ART prior to pregnancy, 78% reported not missing a 
dose of the ART in the past 30 days. In a logistic regression, a unit increase in the scores of medication 
belief, self-efficacy and pregnancy intention all had a positive association with participants reporting perfect 
adherence. Those of low socio-economic status were found to be more likely to report not missing a dose 
when compared to middle and high socio-economic levels.  
Discussion: Generally high levels of adherence were reported in this group, as 85% of women missed one 
or fewer doses of ART in the last 30 days, giving them good enough adherence to potentially achieve viral 
suppression. The results of this analysis are an important first step into characterising the barriers of 
adherence in this growing population. Further research could assist health care workers in identifying 
barriers to adherence in pregnancy.  
 
 
 
 
______________________________________________________________________________________ 
 This article meets the requirements for Epidemiology and Prevention manuscripts as set out in the 
Online Submission and Review System Guidelines for the Journal of Acquired Immune Deficiency 
Syndromes. In keeping with these guidelines, tables referenced in the text can be found after the references. 
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Introduction: 
Viral load is a crucial factor in an HIV-positive person’s health. A suppressed viral load, where HIV 
reaches low or undetectable levels in a person’s blood, has been shown to lead to improved health 
outcomes and longer life. But achieving suppression requires good adherence to antiretroviral therapy 
(ART)1. It has been widely shown that taking ART as prescribed staves off poor health outcomes through 
viral suppression in an HIV-positive population2.  
The success of ART depends on how well it is initiated, implemented and maintained3. Poor 
implementation, where there are delayed or missed doses, can impede viral suppression4. Although there 
are no agreed upon definitions of adherence in ART5, studies have used measures that, depending on the 
medication being studied, range from 80% to 100% compliance4. A systematic review estimates that taking 
over 95% of medication as prescribed can lead to viral suppression6.  
Good adherence is important among HIV-positive pregnant women to prevent mother to child 
transmission (MTCT)7. A woman with an undetectable viral load is at a much smaller risk for MTCT in both 
the ante-8 and post-natal periods9. Good health is closely related to good implementation of ART7, and an 
adherent woman can decrease the frequency of secondary illnesses longer than a non-adherent woman, 
allowing her better quality of life and letting her care for her infant10.  
Adherence is an issue during pregnancy and into the post-partum period11. Women have been 
shown in some studies to have worse adherence to ART than men12–14, and the new complications and 
stresses that come with pregnancy only add to this complex issue6,15,16. However, research on ART 
adherence among pregnant women is in the early stages6,11 and still, little is known about the barriers 
pregnant women face in taking their medication.  
Even less is known6 about an emerging sub-group of this population17: women who do not initiate 
and then terminate ART with each pregnancy, but instead have persisted in taking lifelong ART regardless of 
pregnancy status. These women, who have conceived on ART, have been shown in a paper from the 
European Collaborative Study to have better personal health and healthier babies than women initiating ART 
during their pregnancy8. Because of the introduction of Option B+ parts of Southern Africa and around the 
world, which dictates that pregnant women persist on ART after delivery18, this population of established 
users will only grow. With the adoption of Option B+ in the Western Cape, South Africa, this means that the 
landscape of HIV treatment in the country has changed. Due to the benefits of lifelong adherence, especially 
for mothers, and the lack of knowledge around this emerging group, it is important to describe the barriers to 
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adherence among HIV-positive pregnant women who have conceived on ART.  
Methods: 
As part of the Maternal and Child Health Antiretroviral Treatment (MCH-ART) study, a larger study of 
ART in pregnancy and into the postpartum period, a cross-sectional study of HIV-positive women in 
Gugulethu, Western Cape was conducted. This first phase consisted of a survey of women who presented 
for their first visit at a Midwife Obstetric Unit (MOU) in Gugulethu.  
For inclusion in the study, women were over 18 years of age, pregnant (verified by ultrasound, urine 
test or clinical assessment) and were HIV-positive. Additionally, to be considered for this analysis, 
participants had to have been taking ART for at least four months to be considered on ART prior to 
conception. Participants were excluded if they were not pregnant or if they had a medical, physical or social 
condition that would preclude them from properly consenting to or participating in the study, such as denial of 
HIV status or refusal to take ART.  
After abstraction from participant medical records to check ART status and duration, 502 participants 
from the original 1,544 were eligible for inclusion. During analysis, 16 participants were found to have 
missing questionnaire results and so were excluded from the analysis. However these participants were not 
significantly different from the rest of the sample with regard to the distribution of the outcome variable. The 
final sample size was 486.  
Adherence was measured as the self-reported number of ART pills missed in the last 30 days. This 
was stratified into two groups for a binary outcome, comparing those who reported missing no doses in that 
time period to those who reported missing one or more doses. Self-reported measures of adherence are 
prone to bias, and in some studies have been shown to be unreliable2. To provide some measure of internal 
validity, the outcome measure was validated against other scale measures used in the study.   
Seven assessments were used to measure possible confounders. The Demographics and Medical 
History assessment was created in-house to acquire basic demographic information, such as age and data 
used to create a variable for socio-economic status (SES). Information was also collected on previous ART 
use, hospitalisations and pregnancy.  
The HIV Treatment Knowledge (HIV-TK) and the HIV/AIDS Knowledge Inventory (HIV-KI) both used 
true and false questions, with “Don't know” and “Refuse” options, to quantify participant's knowledge of the 
virus. The HIV-TK was adapted from Wagner et al.19, and asked eight true and false questions to measure 
participant's understanding of how ART protects women along with their infants. The HIV-KI was adapted 
from Kalichman and Simbayi20, and had three additional questions appended to the original: “Can a woman 
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give HIV/AIDS to her baby during breast feeding?”; “Does formula feeding reduce the risk of a baby getting 
HIV?” and “Do caesarean sections reduce the risk of a baby getting HIV?” 
A composite score was generated for both sets of responses, with a point given for a correct 
response and no points given for an incorrect response or a refusal.  
The other four questionnaires used scale assessments. The Beliefs About Medications 
Questionnaire (BMQ) was taken from the assessment from Horne et al.21, and uses seven items from the 
original. It uses a five-item response scale, ranging from “Strongly Disagree” to “Strongly Agree,” with an 
option for “Refuse.” In the BMQ, participants were asked their opinions on statements about their 
medication's ability to keep them and their infant healthy. A composite score was generated for each 
participant, with the highest value of five given to the response expressing the strongest belief in the 
medication. There were no participants who refused to answer a question on this assessment.  
The Adherence Self-Efficacy Scale (ASE), adapted from Chesney et al.22, measured confidence and 
ability to adhere to medication during daily tasks, pregnancy and into the post-partum period. The scale used 
five items, with the lowest response being “Not confident at all,” up to “Very confident.” Again, a “Refuse” 
option was given. A composite score was calculated for each participant, with, again, the highest value of 
five for an answer of “Very Confident.” There was one “Refuse” response, which was given the lowest 
response of one.  
The London Measure of Unplanned Pregnancy (LMUP), adapted from Barrett et al.23, uses six items 
to determine pregnancy intention. A composite score was generated for each participant. Items were scored 
according to the scoring guide provided in the original article's appendix23, and analysed by its suggestion. 
To interpret: the lower the participant’s LMUP score, the more unintended the pregnancy.  
Maternal Adherence Assessment (MAA) was adapted from an article from Wilson et al.24. This 
assessment was used to measure medication side effects, adherence and reasons for non-adherence. A 
composite score was generated for adherence by adding up the following questions from this assessment: 
“Since you started taking them, how would you rate how well you usually do taking your HIV medicines in the 
way you are supposed to?” (Q8); “In the last 30 days, how good a job did you do at taking your HIV 
medicines in the way that you were supposed to?” (Q11); “In the last 30 days how often did you take your 
HIV medicines in the way that you were supposed to?” (Q12); “How hard is it for you to take your HIV 
medicines in a way you are supposed to?” (Q13). The highest value was assigned to the most desirable 
responses for each question, so that participants with the highest composite scores were self-reporting 
better ART adherence.  
An analysis of the data was undertaken to describe the characteristics of study participants at 
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enrolment (see Table 1). A similar univariate analysis was conducted on the self-reported adherence 
measures used in this study (Table 2). A bivariate analysis was then conducted, comparing variables 
between those who reported missing no doses of their antiretrovirals in the last 30 days and those who 
reported missing one or more doses (Table 3). Categorical variables were compared using either chi-
squared tests or Fisher's exact tests. Numerical variables were compared using two-sample t-tests and 
Wilcoxon Rank-sum tests. All comparisons used a 95% level of significance.    
Cronbach's alpha was derived for each of the psychometric assessments (see Table 4; for a more 
detailed table, see journal article Appendix A). These six measures were previously validated; however 
alphas were calculated to assess their reliability with regard to this specific population. A cut-off of 0.7 was 
used and has generally been recognised as a good benchmark for internal consistency and reliability25. 
Scores from assessments with alphas below this cut-off were also used in model building, however a test 
does not need to approach a perfect scale to be interpretable26 and scales with low inter-item correlations 
can still yield results.  
A logistic regression model was built using variables identified in a review of the literature as 
possible confounders (see Table 5). Variables were organized into three categories: interpersonal, 
intrapersonal and background16. A prospective step-wise procedure was used to select the best-fitting model 
to describe the statistically significant barriers to adherence among this population. 
The University of Cape Town’s Faculty of Health Sciences Human Research Ethics Committee gave 
ethical approval for this analysis.  
 
Results: 
Of the 486 HIV-positive pregnant women included in this analysis, all were African, 98% of 
participants spoke isiXhosa and the mean age was 31 years. Among participants, the matriculation 
prevalence was 22%, and 38% reported working either full-time or part-time. Using the responses for level of 
educational attainment, employment status, housing type and number of amenities in the household, a 
categorical variable was created for SES. The low SES bracket had 30% of participants; 36% of participants 
were in the middle bracket and 34% in the high bracket.  
Almost all of participants reported currently being in a relationship (99%). The median length of 
relationships reported was four years, with 50% of participants who were in a relationship saying that they 
were married or living with their partner. The vast majority of participants reported disclosure of their status to 
at least one other person (99%), with 86% of those reporting having done so to their significant other.   
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Participants reported being on ART for a median of 3 years (IQR 1;5) and 58% of participants 
reported knowing the name of their medication. The median number of doses missed in the past 30 days 
was 0, though some participants reported missing up to 30 doses. One or more doses were missed by 22% 
of participants in the past 30 days.  
The bivariate analysis showed a statistically significant difference between outcome groups with 
regards to SES category, with those reporting missing at least one dose in the past 30 days having a higher 
proportion of participants in the highest SES category compared to those who reported missing no doses 
(42% vs. 32%). Those who reported missing no doses had a statistically significant higher median score for 
medication belief (27.5 vs. 26), maternal adherence (19 vs. 17) and pregnancy intention (5.5 vs. 3). The ASE 
showed no difference in median score between the groups, however the lower limit for the IQR for those 
reporting missing no doses was higher and a rank-sum test showed a statistically significant difference 
between the two medians ([73;75] vs. [66.5;75]). Of those who missed no doses, 87% also reported 
disclosing their status to their male partner, compared to 79% of those who reported missing one or more 
doses.  
Both the HIV-TK and the HIV-KI had low alphas, and so were poor measurement tools in this 
population (alpha=0.32; alpha=0.40, respectively; see Table 4). In both of these assessments, participants 
answered a high proportion of each question correctly. However, due to the low alphas, these assessments 
were found not to be reliable measures of HIV and ART knowledge in this population. The four other 
psychometric assessments used all had high alpha values and thus provided reliable measures in this 
population.  
Table 5 has four panels, each fitting a model a different way to explore the relationship between 
adherence and the variables measured in this study. Panel 1 shows the unadjusted odds for each variable 
with respect to reporting no missed doses of ART in the past 30 days. Panel 2 reports the adjusted odds 
fitting age and SES category with each variable. Adjusting for age and SES did not appreciably change any 
of the odds when compared to the unadjusted odds in Panel 1. Panel 3 reports a model adjusting for age 
and SES, along with all of the scale assessments used in the study. In this panel, the ASE, HIV-KI and the 
HIV-TK all contributed insignificantly to the model's fitting of the outcome measure.  
Panel 4 fits a full model including only variables that significantly contributed to improving the fit. A 
Hosmer and Lemeshow goodness-of-fit test showed the model to be an appropriate fit for the data (p=0.30). 
The largest effects were seen with SES category, maternal adherence and medication belief scores. For 
every one unit increase in maternal adherence score, a participant was 52% more likely to report missing no 
doses in the last 30 days. A higher SES was found to be harmful to ART adherence in this model, with those 
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in the middle and high SES brackets 59% and 66% less likely to report missing no doses in the past 30 days 
compared to those in the low SES bracket, respectively.  
Discussion: 
 This study is one of the first in South Africa to examine adherence in HIV-infected women who 
conceive while established on ART. The principal objective was to determine the factors associated with 
adherence in order to identify risk factors in this understudied but important and growing population that may 
be amenable to intervention. The analysis suggests that adherence self-efficacy; medication beliefs and 
pregnancy intentions were associated with higher self-reported adherence.  
Though they individually had small and statistically insignificant effects, the inclusion of self-efficacy 
and pregnancy intention in combination significantly improved the fit of the model, and their observed 
positive associations were in keeping with the literature. Self-efficacy has been previously shown to impact 
adherence6,27, and has been acknowledged as an important step in affecting long-term change in health 
behaviour28. Pregnancy intention speaks to participants’ fertility decisions and control over their reproductive 
health29. Those with scores indicating intended pregnancies were found to be more likely to not miss a dose, 
which might mean that these women are more efficacious or in situations that allow them more agency over 
their health behaviour. 
It is a natural fit for participant’s strong belief in their medication to affect their adherence, and 
previous studies have shown that those who feel that they need their medication and have faith in its ability 
to keep them healthy have better adherence than those with negative perceptions of their medication6,19,21. 
Horne et al. suggested that knowledge of the illness being treated by the medication might also affect 
adherence and be modified by medication belief21. This was not found to be true in this analysis, as neither 
HIV-TK nor HIV-KI scores were statistically significant variables in the model.  
The association found in this model with SES, with those of low SES being more likely to report good 
adherence than those of middle and high SES, is counter to the literature, as low SES has previously been 
associated with poor adherence to ART6,16,30. In this study, participants in the lowest SES bracket were 
significantly more likely to report not currently being employed when compared to those in the mid and high 
brackets (p<0.01). One possibility in explaining this relationship is that the women who are employed have 
families who are dependent on them and are unable to afford to take time off work16 to access health care. 
The strongest association in the model was with maternal adherence score. This association, as well 
as the adherence assessment’s strong internal consistency, speaks to the reliability of the self-reported 
measures in the study. A correlation matrix (see journal article Appendix B) showed a statistically significant 
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negative linear relationship between the number of missed doses reported by participants and how well they 
rated their adherence in a number of questions (rating adherence since initiation, in the last 30 days, etc.), 
though some of these correlations were weak. These correlations are interesting as they were all statistically 
significant, despite the fact that each measure used different measures of adherence or different time scales. 
It would be interesting for future research to further explore this topic, and to look at the correlation between 
measures using adjectival, adverbial and numerical scales in greater detail. 
As this analysis was conducted with data drawn from a cross-sectional study, we cannot 
conclusively determine the causality of any of the factors significantly associated with the outcome in the 
model. For example, being of higher SES itself probably would not cause someone to be non-adherent to 
ART, though the association observed in this study might speak to some underlying factors in participants’ 
lives that might affect their adherence, such as work schedules and issues with disclosure of status to 
employers16. It is easier to hypothesize that some factors in the model came before poor adherence, like 
medication belief and self-efficacy22. Another limitation of this analysis is that some risk factors for poor 
adherence to ART identified in the literature were not measured, like depression1,11,31 and substance 
abuse6,11,27. Therefore their association with adherence cannot be adjusted for. There was some missing 
data, leading to the exclusion of 16 participants. Some of this loss was to allow ART duration to be used in 
model building as it has previously been shown to have significant associations with adherence2,32, however 
it was statistically insignificant. Ultimately, participant viral load was not considered for this analysis, because 
viral load can be affected by details such as what line of treatment a participant is on and drug resistance33, 
neither of which were measured in this part of the study. Future research into the association between viral 
load and adherence in the population could yield interesting results.   
Finally, there is the issue of interpretation of these results. This article’s strength, the emerging 
population studied, needs to be carefully defined and considered when looking at these results. Because this 
is such a unique group, the findings of this article should not be seen as transferable to other populations. 
This article speaks specifically to the barriers faced by women who are established on ART, HIV-positive and 
pregnant, and should not be stretched beyond those constraints. Further research should be done into 
adherence among male and non-pregnant female established users of ART to provide a complete picture of 
adherence patterns in the Western Cape and South Africa.  
Keeping the above limitations in mind, there are a number of strengths for this study. The objectives 
of this research article address a critical gap in the literature on ART adherence6. It sheds some light on the 
factors that affect adherence among this group using tools that take less than 20 minutes to complete, are 
validated in this population and already translated into the local language, isiXhosa. The model built in this 
 10 
analysis could have important future use with the expansion of ART delivery in the Western Cape due to the 
provincial health department’s adoption of Option B+18. As this model has only a few significant variables, all 
of which can be measured speedily, this could be applied in a busy clinic setting to help identify poor 
adherers and provide additional support to encourage taking ART. With piloting to determine optimal cut-offs 
and sensitivity for a final composite score from the measurements, this model could become a useful tool for 
healthcare workers looking for a quick and easily interpretable assessment. 
Enabling women to maintain their health and supporting them as they take their ART is of great 
importance to public health in South Africa. Achieving the World Health Organisation’s goal of elimination of 
mother to child transmission by 2015 requires better adherence throughout the PMTCT cascade12. More 
research done into the barriers of adherence in pregnant women will make it easier for healthcare providers 
to identify potential non-adherers and to better support those on ART to reach this goal.  
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Tables 
 
Table 1: Baseline characteristics of participants in study 
Demographic Variables                     
 N=486 
 
N (%) 
Age                                                 Mean (Std)  31 (5) 
African Ethnicity 486 (100) 
Home language                                 isiXhosa 476 (98) 
Finished secondary school 105 (22) 
Working                                                      187 (38) 
Household income from  
full time employment 
282 (58) 
Type of home               
                                    Shack/informal dwelling 
 
282 (58) 
House/flat/hostel 204 (42) 
SES category                                             
Low 
 
144 (30) 
Middle 177 (36) 
High 165 (34) 
Median number of times pregnant (IQR) 3 (2;3) 
LMUP category 
Planned 
 
131 (27) 
Ambivalent 126 (26) 
Unplanned 229 (47) 
Currently in a relationship 480 (99) 
Married/cohabitating 240 (50) 
Median length of relationship (IQR)  4 (2;8) 
Current partner is the parent of any of your 
children 
478 (100) 
Mean number of family members disclosed 
to (std) 
5 (3) 
Told anyone that you were HIV positive 481 (99) 
Husband/partner/boyfriend  415 (86) 
Mother  271 (56) 
Sister   357 (74) 
Health professionals  481 (100) 
Friends  318 (66) 
Median ART duration (years) (IQR)  3 (1;5) 
Median number of missed doses in last 30 
days (IQR) 
 
0 (0;0) 
0 378 (78) 
1 34 (7) 
2 37 (8) 
3-10 31(7) 
30 6 (1) 
 
Std, standard deviation; SES, Socio-economic status; LMUP, London Measure of Unplanned Pregnancy; 
ART, antiretroviral therapy; IQR, interquartile range 
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Table 2: Baseline ART and adherence characteristics of participants 
Adherence measures  
N=486 
 
N (%) 
Know the name of their current ART regimen                                                                                                283 (58)
Participants who have never stopped ART regimen 440 (91) 
Since you started taking them, how would you rate how usually 
do taking your HIV medicines in the way you are supposed to?  
Poor or fair 
 
 
20 (4) 
Good 218 (45) 
Very good 181 (37) 
Excellent 67 (14) 
Now think about the last 30 days. How would you rate how well 
you did taking your HIV medicines?  
Worse than usual 
 
 
76 (16) 
Better than usual 8 (2) 
About the same as usual 402 (83) 
How hard is it to take you medication as you are supposed to?  
Extremely or very hard 8 (2) 
Somewhat hard 28 (6) 
Not very hard 205 (42) 
Not at all hard 245(50) 
In the last 30 days, how good a job did you do at taking your HIV 
medicines in the way that you were supposed to?  
Very poor or Poor 
 
 
10 (2) 
Fair 24 (5) 
Good 182 (37) 
Very good 182 (37) 
Excellent 88 (18) 
In the last 30 days how often did you take your HIV medicines in 
the way that you were supposed to?  
Never, rarely or sometimes 
 
 
16 (3) 
Usually 165 (34) 
Almost always 114 (23) 
Always 191 (39) 
 
ART, antiretroviral therapy 
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Table 3: Bivariate analysis of outcome measure and variables of interest  
 
 Missed a dose in past 30 
days (n=108) (22) 
Has not missed a dose in 
past 30 days (n=378) (78) 
P-value 
 
Age mean (std) 
 
31 (5) 
 
31 (5) 
 
0.54 
SES score                Low 21 (19) 123 (33)  
 
 
0.02 
Middle 42 (39) 135 (36) 
High 45 (42) 120 (32) 
Finished high school 25 (23) 80 (21) 0.66 
Median ASE score (IQR) 75 (66.5;75) 75 (73;75) 0.01 
Median MBQ score (IQR) 26 (23;31) 27.5 (24;33) <0.01 
Median MAA composite 
score (IQR) 
17 (15;19) 19 (17;21) <0.01 
Median HIV-KI score (IQR) 6 (5;7) 6 (5;7) 0.99 
Media HIV-TK score (IQR) 7 (6;7) 7 (7;7) 0.24 
LMUP score (IQR) 3 (1;9) 5.5 (3;10) <0.01 
LMUP Pregnancy Intention    
Planned 20 (19) 111 (29)  
Ambivalent 29 (27) 97 (26)  
Unplanned 59 (55) 170 (45) 0.07 
Know ART regimen 61 (56) 222 (59) 0.68 
Median years on ART 
(IQR) 
3 (1;5) 3 (2;5) 0.38 
Disclosed HIV status  106 (98) 375 (99) 0.31 
Median number of family 
members disclosed to 
(IQR)  
4 (3;8) 4 (2;7) 0.39 
Disclosure to male partner 85 (79) 330 (87) 0.04 
Detectable (≥50 units) viral  
load 
30 (28) 74 (20) 0.07 
 
Std, standard deviation; SES, Socio-economic status; ASE, Adherence Self-efficacy Scale; IQR, interquartile 
range; BMQ, Beliefs About Medication Questionnaire; MAA, Maternal Adherence Assessment; HIV-KI, 
HIV/AIDS Knowledge Inventory; HIV-TK, HIV Treatment Knowledge Score; LMUP, London Measure of 
Unplanned Pregnancy; ART, antiretroviral therapy 
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Table 4: Cronbach’s Alphas for Psychometric Scale Measures  
 
Name of Scale Cronbach's Alpha 
Assessment of Self-efficacy 0.93 
Beliefs About Medication Questionnaire 0.80 
Maternal Adherence Assessment 0.84 
London Measure of Unplanned Pregnancy  0.88 
HIV Treatment Knowledge 0.32 
HIV/Aids Knowledge Inventory 0.40 
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Table 5: Models predicting not missing a dose in the last 30 days  
 
 Panel 1 (unadjusted) Panel 2 (adjusted for age 
and SES) 
Panel 3 (model of psychometric 
measures adjusted for age and 
SES) 
Panel 4 (full model) 
 OR CI OR CI OR CI OR CI 
Sociodemographic Factors 
Age 1.01 (0.97;1.06)   1.00 (0.95;1.06)   
SES (vs. Low) 1 1   1 1 1 1 
Middle 0.55 (0.31;0.98)   0.41 (0.21;0.81) 0.41 (0.21;0.81) 
High 0.46 (0.26;0.81)   0.33 (0.17;0.66) 0.34 (0.17;0.68) 
Finished secondary school 0.89 (0.53;1.49) 1.15 (0.66;2.02)     
Intrapersonal Factors 
ART duration (years) 1.03 (0.95;1.13) 1.03 (0.94;1.13)     
MBQ Score 1.07 (1.02;1.12) 1.07 (1.02;1.12) 1.16 (1.09;1.23) 1.17 (1.10;1.23) 
ASE Score 1.04 (1.01;1.08) 1.05 (1.02;1.08) 1.03 (1.00;1.07) 1.03 (1.00;1.07) 
MAA Score 1.35 (1.24;1.47) 1.36 (1.25;1.49) 1.52 (1.36;1.70) 1.52 (1.36;1.69) 
LMUP Score 1.09 (1.03;1.15) 1.10 (1.03;1.16) 1.07 (1.00;1.14) 1.07 (1.00;1.14) 
HIV-TK Score 1.20 (0.96;1.51) 1.20 (0.95;1.51) 1.11 (0.84;1.46)   
HIV-KI Score 1.02 (0.87;1.19) 1.04 (0.89;1.22) 1.07 (0.89;1.28)   
Interpersonal Factors 
Disclosed status to anyone 2.36 (0.39;14.30) 2.59 (0.42;16.07)     
Disclosed status to male 
partner  
1.86 (1.07;3.22) 1.95 (1.11;3.42)     
 
SES, Socio-economic status; OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy; BMQ, Beliefs About Medication Questionnaire; ASE, Adherence 
Self-efficacy Scale; MAA, Maternal Adherence Assessment; LMUP, London Measure of Unplanned Pregnancy; HIV-TK, HIV Treatment Knowledge Score; HIV-KI, 
HIV/AIDS Knowledge Inventory
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Phase I Informed Consent Form 
WHAT ARE THE POTENTIAL RISKS? 
If you decide to participate, you may feel uncomfortable about some of the personal questions you are 
asked about your health or your pregnancy. You may refuse to answer any question that you do not 
want to answer. T here is some risk in sharing personal and medical infom1ation. We will be careful to 
keep all your information as private as possible. 
Drawing blood is normally done as part of routine medical care and presents a sl ight risk of discomfort. 
Experienced staff will draw blood under sterile conditions in order to protect you against these risks. 
WHAT ARE THE POTENTIAL BENEFITS? 
There is no direct benefit to you if you take part in this study but if we identify any health care problem 
during the course of the study, we will make sure you are referred to the appropriate health care 
services. The information gained in this study may help to improve ART services for HIV -infected 
pregnant women in Cape Town, the Western Cape Province, and across South Africa. 
WHAT ARE THE ALTERNATIVES TO TAKING PART? 
The alternative to taking part in this study is to continue with your usual care at the MOU. 
WHAT ABOUT CONFIDENTIALITY? 
If you agree to take pa1t, all information collected during the study will be kept strictly confidential. 
Your name will not be written on the study forms and will not be used in connection with any 
information or lab specimens that are collected as part of the study. 
All study materials will be stored in locked fi ling cabinets. Only study staff and personnel involved in 
routine audits will have access to these materials. All staff involved in data collection and management 
will get specific training in confidentiality. 
Even with these procedures in place, if the study staff learns that you are a risk to yourself or someone 
else or of possible chi ld abuse and/or neglect, study staff will tell the proper authorities. 
WILL I BE GIVEN ANYlliiNG FOR TAKING PART? 
No, there is no compensation for taking part in the study today. 
ARE THERE ANY COSTS? 
There is no cost for being in this study. 
CANILEAVETHESTUDY? 
You have the right to decide not to not take part in the study, to refuse to answer any questions, or to 
withdraw from the study at any time without any penalty. It will have no effect on the care that you 
receive at the Gugulethu MOU or any other health facility. 
FUTURE USE OF SPECIMENS: 
Page 2 of 4 
Version 3.0 31 Oct 20 13 Columbia University IRB 
IRB·AAAK8059 
IRB Approval Date: 10·28,.2014 
for uge until: 10128.·2014 
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Phase I Informed Consent Form 
If you agree, any leftover blood from the sample you have provided for this research project may be 
used for future HIV related research. It is possible that these stored samples may be tested to see if the 
HIV in your blood is resistan t to an y types of HIV medications or to look at other questions related to 
HIV. 
At this time, we cannot provide details of when this testing may be conducted. However, additional 
test ing will not be done using these stored samples w ith out the approval of th e appropriate ethics 
committees involved in this research. 
If you agree to let us keep your stored samples for future research, th ey may be kept in a locked freezer 
for up to 5 years. If we do use yow- samples in the fu ture, your name or other identifiers will not be 
included with this information (as with the rest of the information we collect for this study). 
Please initial below to indicate whether or not you give permission for your specimens to be used fo r 
fu ture research. You may still remain in the study, no matter which you choose. 
___ (initial) I agree to have my blood stored for future research. 
___ (irlitial) I agree to have my blood stored for future research related to this study ON LY. 
___ (ini tial) I do NOT agree to the storage of my blood for future research. 
DO YOU HAVE ANY QUESTIONS? 
If there is anything that is unclear or if you need fu rther information, p lease ask us and we will provide 
it. 
Do you have any questions? 
FOR ADDITIONAL INFORMATION: 
If you have any questions or have any problems while taking part in this research study, you should 
contact: 
Dr Landon Myer 
School of Public Health and Family Medicine 
Faculty of Health Sciences, U niversity of 
CapeTown 
Tel: 021 406 6661 
Email: Landon.Myer@uct.ac.za 
Dr Elaine Abrams 
ICAP, Columbia University 
Mailman School of Public Health 
College of Physicians and Surgeons 
Tel: + 1 212 342 0543 
Email : ejal @columbia.edu 
If you have any questions about your ri ghts as a research participant, you may contact the following 
member of the ethics corrunittee: 
Prof Marc Block:man 
Chair, Human Research Ethics Commi ttee 
Faculty of Health Sciences, University of Cape 
Page 3 of 4 
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Tel: + I 212 305 5883 
Columbia University IRB 
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IRB Approval Date: 10·28,.2014 
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Phase I Informed Consent Form 
Town 
Tel: 021 406 6338 
CONSENT STATEMENT: 
I have read this form, or someone has read it to me. I have been offered a copy of this consent form. I 
was encouraged and given time to ask questions. I agree to be in this stud y. I know that after choosing 
to be in this study, I may withdraw at any time. My being in the study is voluntary. I understand that 
whether or not I participate wiU not affect my health care services received today, or at any time in the 
future. 
Please indicate your consent with your signature. 
Voh.mteer' s name __________________ _ 
Signature of Volunteer Date 
Staff member's name ________________ _ 
Signature of study staff Date 
If the volunteer is unable to read or write the entire counsell ing process must be observed by an 
independent witness who can th en confirm the procedure once the she has given consent. 
Fingerprint of volunteer: 
Witness: 
I confirm that I am independent of the study and that I witnessed th e entire informed consent 
counselling process in the home language of the volunteer 
Witness' s name _________________ _ 
Signature of witness Date 
Thank you. 
Page4 of 4 
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IRB Approval Date: 10·28,.2014 
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MCH-ART: Demographics & Medical History, Phase 1 PID: 1 -_____ _ 
Xhosa-Enqlish of Version 3.0, 15 October2013 
ltyotyombe/ uhlaliso olungahlelwanga = 1 
Shack/informal dwelling 
lndlu yesitena = 2 
8. Uhlala kwikhaya elinjani? Formal house What kind of home do you live in? lfleti/ indlu kamaspala = 3 
Flat/council home 
Enye = 4, chaza: 
Other soecifv 
a. lndlu Hayi/flkl =0 
yangasese Ewe1Yes=1 A tdlet inside 
b. Amanzi 
abalekayo Hayi/flkl =0 
empompo E we!Yes=1 
Running water 
lngaba indlu yakho inazo inside 
9. ezi zinto zilandelayo: c. Umbane Hayi/flkl =0 
Does your house have the following: Electricity inside Ewe/Yes=1 
Read and answer for all 
lsikhenkcisi Hayi/flkl =0 d. 
A refrigerator Ewe/ Yes=1 
e. Umnxeba Hayi/flkl =0 
A telephone Ewe/Yes=1 
f. Umabona Hayi/flkl =0 
kude Ewe/Yes=1 A television 
Bangaphi abantu abahlala kule ndlu bedibene 
10. nawe( abadala,abancinci)? lnani labantu: 
lnduding yourself, how many people (adults and children) live #of people: 
in your house? 
Bangaphi abadala (iminyaka-16 
11 . 
nangaphezulu)bedibene nawe abahlala kule lnani labadala: 
ndlu? #of adults 
How many adults (aged 16 or older), inciuding you, live in your 
house? 
Bangaphi abantwana (iminyaka -15 lnani labantwana: 12. nanganeno ) abahlala nawe? #of children 
How many children (aaed 15 and under) live in your house? 
13. 
Ukhulelwe kangaphi (kudibene nesi isisu)? inani lokukhulelwa: How many times have you been pregnant (including current #of pregnancies: I pregnancy)? 
lngaba ubuzama ukuba nosana ngelixesha Hayi/flkl = 0 
14. ufumanisa ukuba ukhulelwe (Kwesi isisu)? E w e/Yes= 1 
Were you trying to have a baby when you found out you were Andazi/ 1 don't know = 9 I pregnant (in this pregnancy)? 
lnani labantwana: 
15. Bangaphi abantwana obazeleyo? #of children 
How many children have you given birth to? Ukuba = 0, Gqithela ku 020 
If 0, SKIP to 020 
16. Bangaphi kwaba bantwana abaphilayo? lnani labantwana: 
How many of these children are living? #of children 
Bangaphi kwaba bantwana abahlala nawe lnani labantwana: 17. ngoku? #of children 
How many of these children currently live with you? 
Bangaphi kwaba bantwana ekufumaniseke lnani labantwana abaphila nentsholongwane: 18. bakho ukuba baphila nentsholongwane? 
How many of your children have tested HIV-posiUve? 
#of HIV-positive children 
Bangaphi kwaba bantwana baphila lnani labantwana abaphila nentsholongwane abaphilayo 
19. nentsholongwane abasaphilayo? ngoku: How many of these children who have tested HIV- positive are 
currently living? #of HIV-positive children currently alive 
I~ Columbia University IRB I IAB·AAAK8059 IRB Approval Date: 11·27.:2013 Page 2 of 7 ;10r use until: 11 '26'2014 OU<OOO> U O ~UUOOO<O OOU , 
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MCH-ART: Demographics & Medical History, Phase 1 PID: 1 -_____ _ 
Xhosa-Enqlish of Version 3.0, 15 October2013 
Uya thandana ngoku? Hayi/1\tl = 0-+ Gqithela ku Q25 20. SKIPtoQ25 
Are you currently in a relationship? 
Ewe/Yes= 1 
Utshatile = 1 
Married 
Anditshatanga ,ndiya hlalisana =2 
Not married, living together 
21 . Ungaluchaza njani uthando lwakho? Nditshatile, asihlali kunye = 3 
How wouki you describe your current relaUonship? Married, not living together 
Anditshatanga, asihlali kunye = 4 
1\tlt married, not living together 
Enye = 5, cacisa: 
Other. specify 
Lileshe ellingakanani unobudlelwana lxesha lnyanga Months 22. nalomntu? 
How long have you been in a relationship with this person? 
DuraUon in: lminyaka Years ___ 
lngaba eli qabane lakho ngutata womnye 
23. 
wabantwana bakho(kunye nalo Hayi/1\tl = 0 
umkhulelweyo)? E we/Yes= 1 
Is your current partner the parent of any of your children? 
I (including current pregnancy) 
Ulichazele na iqabane lakho ngesimo sakho Hayi/1\tl = 0 24. sentsholongwane? Ewe/Yes= 1 Have you disclosed your HIV status to your current partner? 
Ubukhe wabelana ngesondo nabanye abantu 
ingenguye lomntu uthandana naye? Hayi/1\tl = 0 -+ Gqithela ku Q28 25. -7 SKIP to 0 28 In the last 12 months have you had any sexual 
Ewe/Yes= 1 relaUonshipslsexual partners? (if in a relationship then other 
than this partner) 
Bunjani ubudlelwanebakho namanye a. Umlingane/nditshatile 
amaqabane ngaphandle kweqabane lakho Spouse/ married 
langoku ukuba akhona? b. lqabane lam 
26. What is the nature of your relationship(s)? (other than current Boyfriend partner if applicable) c. lqabane lethutyana 
Casual Partner/One Night Stands 
Rhangqa konke okungqamene nawe. d. Omnye ,cacisa: 
Mark all that apply. Other, specify 
Ubaxelele aba bantu wabelana nabo 
27. ngesondo ukuba uphila nentsholongwane? Hayi/1\tl = 0 
Have you disclosed your HIV status to any of these other Ewe/Yes= 1 
sexual partners? 
Ubuqala ukufumanisa ukuba unentsholongwa Koku ukukhulelwa =1 -7 Gqithela ku 032 
28. 
kagawulayo kolumitho okanye phambi kokuba In his pregnancy SKIPtoQ32 
ukhulelwe? Phambi koku ukukhulelwa =2 
Did you first test HIV positive in this oreanancv or~ Before this pregnancy I oreanancv? 
Kwakunini ukuqala kwakho ukufumanisa Umhla: _ lnyanga: __ Unyaka: ___ 29. ukuba unentsholongwane kagawulayo? 
When did you 1~ test HIV-positive? Day Month Year 
Ndivavanywe ngelixesha ndikhulelweyo = 1 
Tested during pregnancy 
VCT/Ndandifuna ukuvavanywe =2 
VCT!Wanted to be tested 
30. Kwakutheni ukuze oluhlolo lwenziwe? Ndafunyaniswa ndinesifo sephepha (TB) = 3 Diagnosed with Why was this test conducted? TB 
Ndangeniswa esibhedlele = 4 
Admitted to the hospital 
Enye = 5, cacisa: 
Other, specify I :t Columbia L IRB 
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MCH-ART: Demographics & Medical History, Phase 1 PID: 1 -_____ _ 
Xh E r h I V 3 0 15 0 b 2013 osa- ngus 0 erst on . , cto er 
lngaba wawukhulelwe ukuqala kwakho 
31 . ukufumane ukuba unentsholongwane Hayi/N? = 0 
kagawulayo? Ewe/Yes= 1 
Were you preqnant when you first tested HIV-positive? 
Wakhe wanazo iziphumo ezingena chaphaza Hayi/N? = 0 --7Gqithela ku 036 
32. kuvavanyo lwentsholongwane kagawulayo? SKIPto036 
Have vou ever tested neaative on an HIV test? E we/Yes= 1 
Ugqibele nini ukuba neziphumo 
33. ezingenachaphaza zovavanyo Umhla : _ lnyanga: __ Unyaka: ___ 
lwentsholongwane kagawulayo? Oay Month Year 
When did vou last test HIV-neaative? 
Ndivavanywe ngelixesha ndikhulelweyo = 1 
Tested during pregnancy 
Kwakutheni ukuze uvavanywe ngelo xesha? 
VCT/Ndandifuna ukuvavanywe =2 
VCT!Wanted to be tested 
34. What was the reason for you doing the HIV Ndafunyaniswa ndinesifo sephepha (TB) = 3 Diagnosed with 
test? TB 
Why did you test at that time? Ndangeniswa esibhedlele = 4 
Admitted to the hospital 
Enye = 5, cacisa: 
Other, specify 
Wawukhulelwe ngeloxesha uvavanyelwa Hayi/No= 0 35. intsholongwane? Ewe/Yes= 1 Were you preqnant at the Ume of that test? 
Wakhe waxelela nabanina ukuba Hayi/N? = 0 --7Gqithela ku 039 
36. unentsholongwane kagawulayo? SKIP to 0 39 
Have you told~ that you are HIV-posiUve? Ewe/Yes= 1 
Ngawaphi amlungu osapho lwakho owaxeleleyo ngesimo sakho sentsholonwane? 
Which of your family members have you told about your HIV status? 
37. Nceda phendula lombuzo ngelungu ngalinye losapho oludweliswe ngezantsi. Please answer this quesUon for each of the family members listed below. 
Wamxelele u _______ ukuba unentsholongwane kagawulayo? 
Have _you told your that you are HIV positive? 
Umyeninqabane 
Hayi/No= 0 
a. Ewe/Yes= 1 Husband/partner/boyfriend N/A = 9 
Umama Hayi/No= 0 b. Ewe/ Yes= 1 
Mother N/A = 9 
Utata 
Hayi/No= 0 
c. Ewe/Yes= 1 
Father N/A = 9 
Udade 
Hayi/No= 0 
d. Ewe/ Yes= 1 Sister N/A = 9 
Umtakwenu Hayi/No= 0 e. Ewe/ Yes = 1 
Brother N/A = 9 
lntombi Hayi/No= 0 I. Ewe/Yes= 1 
Daughter N/A = 9 
Unyana Hayi/No= 0 g. Ewe/ Yes= 1 Son N/A = 9 
Umalume Hayi/No= 0 h. Ewe/Yes= 1 
Uncle N/A = 9 
U-anti Hayi/No = 0 i. Ewe/Yes= 1 Aunt N/A = 9 
I~ Columbia University IRB I IRB·AAAK8059 Page 4 of 7 IRB ~:;~o:!! ~~!~~ ~~~~,:~~~ "" ouoJ v ~vu""~"v • 
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MCH-ART: Demographics & Medical History, Phase 1 PID: 1 -_____ _ 
Xh E r h I V 3 0 15 0 b 2013 osa- ngus 0 ers1on . , cto er 
Umza wesikhomo Hayi/No = 0 j . Ewe/Yes= 1 Male cousin N/A = 9 
Umza wesikhomokazi Hayi/No= 0 k. Ewe/Yes= 1 Female cousin N/A = 9 
Enye indoda yalapha Hayi/No= 0 I. Ewe/Yes= 1 Other male family member N/A = 9 
Esinye isikhomokazi Hayi/No= 0 m. Ewe/Yes = 1 Other female family member N/A = 9 
Ngaphandle kwabantu bakowenu aba badweliswe ngentla,ngubani omnye umntu owamxelelyo ukuba 
38. uphila nentsholongwane?(funda uphendule yonke imibuzo) 
Aside from family members listed above, who else have you told about your HIV status? (read and answer for all) 
Amanesi/ogqira Hayi/N? = 0 a. Ewe/Yes= 1 Health professionals 
N/A = 9 
lqumru lenxaso labantu abaphila Hayi!N:J = 0 
b. nentsholongwane Ewe/Yes= 1 
Support group N/A = 9 
Umntu owabelana naye ngesondo ongahlali Hayi/N? = 0 
c. naye Ewe/Yes= 1 
A sexual partner who does not live with you N/A = 9 
lsihlobo 
Hayi/N? = 0 
d. E we/Yes= 1 Friends 
N/A = 9 
lnkokheli ngokwa kwamoya Hayi/N? = 0 e. Ewe/Yes= 1 Spiritual leader 
N/A = 9 
Umntu okuqashileyo/wayekuqashile Hayi/N? = 0 f. Ewe/Yes= 1 Current or former employer N/A = 9 
Ukuchaza esidlangalaleni Hayi/N? = 0 g. Ewe/Yes= 1 Public disclosure! community 
N/A = 9 
Abanye, chaza: Hayi/N? = 0 h. Ewe/Yes= 1 Other, specify 
N/A = 9 
Wakhe wakhulelwa phambi koku Hayi/N? = 0 -?Gqithela ku 045 
39. ukukhulelwa? SKIPto045 
Have you ever been pregnant before this pregnancy? Ewe/Yes= 1 
Ngokuya ubukhulelwe ngaphambi koku 
ukukhulelwa wawuke wanikwa amayeza okhusela 
usana lungosuleleki yintsholongwane (ezeku Hayi/N? = 0 -?Gqithela ku 045 
40. khusela umntwana hayi amachiza okutho malalisa SK/Pto045 
intsholongwane wobomi bonke) E we/Yes= 1 
When you were pregnant before this pregnancy have you ever 
been given medication at the clinic to keep your baby from 
I qettinq HIV infected? (prophylaxis NOT lifelonq ART) 
Ukuba nguEwe, zingaphi izisu ufumane Ia 
41 . machiza ngesisizathu? lnani lezisu: ---
If yes, during how many pregnancies have you received #of pregnancies 
medication for this purpose? 
Columbia University IRB 
IRB·AAAK8059 
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MCH-ART: Demographics & Medical History, Phase 1 PID: 1 -_____ _ 
Xh E r h I V 3 0 15 0 b 2013 osa- ngus 0 ers1on . , cto er 
Kwezi zisu siyi __ ofumene kuzo amachiza, 
zingaphi izisu otye kuzo iipilisi ngelixesha Ngoku wawubeleka 
42. ubelekayo qha? Only at Delivery (Nevirapine) #: For the _ pregnancies that you received medicaUon, For how Ngelixesha ukhulelwe 
many pregnancies did you take pills while you were pregnant While you were pregnant {AZT)? #: ___ 
and for how many pregnancies did you take pills only at 
delivery? 
Bekunini ukugqibela kwakho ukufumana Ia 
43. machiza ngesisizathu? Umhla:_ lnyanga: __ Unyaka: ___ 
When was the last ttme that you received medication for this Day Month Year 
I purpose? 
Uwafumene phi Ia machiza ukugqibela lgama lekliniki : 44. kwakho? 
Where did you receive the medication the last time? 
Name of clinic: 
Wawuke wawathatha amachiza 
45. 
okuthomalalisa intsholongwane (awobomi Hayi/No= 0 -? Skip to 051 
bakho bonke) Ewe/Yes= 1 
Have you ever taken triple drug anUretroviral th erapy (lifelong 
ART)? 
Ukuba nguEwe, ingaba wawafumana 
46. amachiza okuthomalalisa intsholongwane lgama lekliniki : 
ukugqibela kakho? Name of clinic: 
If yes, where did you receive ART the last time? 
Uqale nini ukutya Ia machiza okuthomalalisa Umhla : _ lnyanga: __ Unyaka: ___ 47. intsholongwane kagawulayo? 
When did you start taking ART? 
Day Month Year 
Usawatya amachiza okuthomalalisa Hayi/NJ = 0 48. intsholongwane kagawulayo? Ewe/Yes= 1-? SKIP to 051 Are YOU sUI/ on ART? 
Ukuba nguHayi,uyeke nini ukuwatya 
49. amachiza okuthomalalisa intsholongwane Umhla : _ lnyanga: __ Unyaka: ___ 
kagawulayo? Day Month Year 
If No, when did you stop takinq ART? 
Columbia University IRB 
IRB·AAAK8059 
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8. 
9 . 
10. 
11. 
12. 
13. 
14. 
15. 
MCH-ART: Adherence Self-efficacy Phase 2 1st visit 
Xhosa-English Version 2.1 , 26 Jan 2013 
Xa uziva ugula? 
IMJen you are feeling sick? 
Xa usele utywala? 
IMJen you dtink alcohol? 
Xa ungafuni kukhunjuzwa nge HIV/AIDs? 
IMJen you don! want to be reminded about HIVIAIOS? 
Xa kuthetha ukuthatha amayeza phambi kwabantu 
abangakwaziyo ukuba uphila ne ntsholongwane 
kagawulayo? 
IM1en l means taking your medications in front of people who donf 
k/'ION you at!l HIV+? 
Xa uziva ugula kuba ukhulelwe? 
IMJen you are feeling sick from your pregnancy? 
Xa uthatha unakekelo losana lwakho? 
IM1en you are busy taking care of your baby? 
Xa uncancisa usana ibele? 
IMJen you are breast feeding your baby? 
Xa uziva udiniwe ukuvuka nosana lwakho? 
IMJen you are tired from waking up wlh your baby? 
Date completed: _ _ I ___ I ___ _ 
DateofQC: __ / ______ _ 
Page 2 of 2 
PID: 2 - _____ _ 
1 2 3 4 5 9 
1 2 3 4 5 9 
1 2 3 4 5 9 
1 2 3 4 5 9 
1 2 3 4 5 9 
1 2 3 4 5 9 
1 2 3 4 5 9 
1 2 3 4 5 9 
uthetha ukuthi uthetha kuthi utheth a ukuthi 
akuqinisekanga uqinisekile nje uqinisekile Ndiyala 
kori<e kancinci ngokupheleleyo Refuse 
Not confident at all Moderatoly 
confident Very confident 
Signed counsellor completing CRF: -----------
Signed measurement nurse:---------
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12. 
13. 
14. 
MCH-ART: Maternal adherence Phase 1(mmen on ART) 
X-E Version 1.0 13 May2013 
Kwezi ntsuku zi-30 zidlulileyo,kukangaphi usitya amachiza akho 
entsholongwane ngendlela omele kuwatya ngayo? 
In the last 30 days how o"en did you take your HIV medicines in the way that you 
were supposed to? 
Kunzima kangakanani ukutya amachiza akho entsholongwana 
ngendlela omele kukuwatya ngayo? 
How hard is it for you to take your HIV medicines in a way you are supposed to? 
Kwintsuku ezi-30 ezidlulileyo ,zeziphi izinto ezibangele ulibale, 
okanye ezenze kubenzima ukutya amachiza akho? 
In the past 30 days which of the following things made you miss a pill or made it 
hard for you to take your pills? 
Zifunde zonke.Urhangqe zonke ezikhe zakwehlele . 
Read all. Circle as many as apply. 
Page 2 of 3 
P10:1- ____ _ _ 
Zange-1 
Never 
Kumbalwa=2 
Rarely 
Ngamanye amaxesha=3 
Sometimes 
Ngesiqhelo = 4 
Usually 
Malunga lonke ixesha=5 
Almost always 
Lonke ixesha=6 
Alwavs 
Kunzima kakhulu kakhulu=1 
Extremely hard 
Kunzima kakhulu=2 
Very hard 
Kunzima nje=3 
Somewhat hard 
Akunzim anga=4 
Nci very hard 
Akunzim anga kwaphela =5 
Nci hard at a II 
a. 
b. 
c. 
d. 
e. 
f. 
g. 
h. 
i. 
j. 
k. 
Bendingekho ekhaya 
Was away from home? 
Zilahlekile 
Lost your pills? 
Bendixakekile ndisenza omnye 
umsebenzi 
Was busy wlh ciher things? 
Ndilibele 
Simply forgot? 
Bezininzi ipilisi ebekufuneka 
ndizitye 
Had too many pills to take? 
Bendifumana imiphumela 
Was gelling side effects? 
Bendibaleka imiphumela okanye 
ndingaziva mnandi 
Wanted to avoid side effects or were feeling 
bad? 
Bendizinika ikhefu kwipilisi 
Wanted to take a break from the pills? 
Bendingafuni abanye bazi ukuba 
nditya ipili si 
Did nci want cihers to nciice you taking 
medication? 
Kuye kwabakho utshintsho 
kwindlela endisebenza ngayo 
okanye ngendlela endiqhele 
Had a change in daily routine or worl< 
schedule? 
Bendicinga ukuba ipilisi 
ziyasebenza nob a ezinye 
andizityanga 
Thought that the pills would still worl< even if 
Columbia University IRB 
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III. Article Appendices 
 
Appendix A 
 
Psychometric Scale Cronbach's (alpha score bolded if greater than 0.7) 
Self-efficacy (How confident are you that you can stick to your medication schedule...) (Alpha=0.93) 
Question (Item total correlation) Mean (SD) Median Alpha with item deleted 
When your daily routine is disrupted (0.69) 5 (1) Very Confident 0.93 
When the side effects begin to interfere with your daily activities? (0.75) 5 (1) Very Confident 0.92 
On weekends? (0.79) 5 (0) Very Confident 0.92 
When you are busy? (0.80) 5 (1) Very Confident 0.92 
When you are tired? (0.86) 5 (0) Very Confident 0.92 
When you are down or depressed (0.85) 5 (0) Very Confident 0.92 
When you are feeling healthy? (0.82) 5 (0) Very Confident 0.92 
When you are feeling sick (0.63) 5 (1) Very Confident 0.93 
When you drink alcohol (0.62) 5 (1) Very Confident 0.94 
When you don't want to be reminded about HIV/AIDS (0.74) 5 (1) Very Confident 0.92 
When it means taking your medications in front of people who don't know you 
are HIV+ (0.63) 
5 (1) Very Confident 0.93 
When you are feeling sick from your pregnancy (0.75) 5 (0) Very Confident 0.92 
When you are busy taking care of your baby? (0.87) 5 (0) Very Confident 0.92 
When you are breastfeeding your baby? (0.83) 5 (0) Very Confident 0.92 
When you are tired from waking up with your baby? (0.85) 5 (0) Very Confident 0.92 
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Continued Psychometric Scale Cronbach's (alpha score bolded if greater than 0.7) 
Beliefs About Medication (Alpha=0.80) 
My health during my pregnancy depends on my medicines (0.66) 4 (1) Agree 0.78 
My baby's health depends on my medicines (0.68) 4 (1) Agree 0.78 
Having to take medicines during my pregnancy worries me (0.78) 2 (1) Disagree 0.75 
Having to take medicines while I am breastfeeding worries me (0.78) 2 (1) Disagree 0.75 
Without my medicines I will be unable to care for my baby (0.65) 4 (1) Agree 0.78 
I sometimes worry about the long-term effects of my medicines on my baby (0.68) 3 (1) Agree 0.81 
When I am breast feeding my medicines will protect my baby from HIV (0.64) 4 (1) Agree 0.78 
Maternal Adherence Composite Score (Alpha=0.84) 
Since you started taking them, how would you rate how well you usually do taking your 
HIV medicines in the way you are supposed to? (0.83) 
5 (1) Very Good 0.80 
In the last 30 days, how good a job did you do at taking your HIV medicines in the way 
that you were supposed to? (0.90) 
5 (1) Very good 0.75 
In the last 30 days how often did you take your HIV medicines in the way that you were 
supposed to? (0.86) 
5 (1) Almost Always 0.80 
How hard is it for you to take your HIV medicines in a way you are supposed to? (0.72) 4 (1) Not hard at all 0.85 
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Continued Psychometric Scale Cronbach's (alpha score bolded if greater than 0.7) 
London Measure of Unplanned Pregnancy (Alpha=0.88) 
Question (Item total correlation) Mean (SD) Median Alpha with item deleted 
In the month that I became pregnant...  (0.37) 2 (1) I/we always used contraception 0.91 
 In terms of becoming a mother (first time or again), I feel that my 
pregnancy happened at the... (0.87) 
1 (1) OK, but not quite the right time 0.84 
Just before I became pregnant...(0.96) 1 (1) I did not intend to become pregnant 0.81 
Just before I became pregnant...(0.96) 1 (1) I had mixed feelings about having a baby 0.81 
Before I became pregnant... (0.91) 1 (1) We never discussed having children together 0.83 
Before you became pregnant, did you do anything to improve your 
health in preparation for pregnancy? (0.48) 
0 (0) No actions 0.9 
HIV Treatment Knowledge (Alpha = 0.32) 
Question (Item Total Correlation) Percentage correct (%) Alpha with item missing 
Antiretroviral medication aims to reduce or suppress the activity of the HIV virus in the 
body. (0.13) 
True (100) 0.32 
Taking antiretroviral medications on schedule helps keep the right amount of medicine in 
one’s system. (0.36) 
True (97) 0.28 
Viral load measures the amount of HIV virus in the blood.  (0.51) True (87) 0.28 
Sometimes lab results say that a person’s viral load is “undetectable.” This means that 
there is no virus left.  (0.41) 
False (87) 0.34 
Taking antiretroviral therapy exactly as prescribed is likely to reduce viral load.  (0.25) True (99) 0.31 
Taking antiretroviral therapy can reduce a child's risk of becoming HIV infected during 
pregnancy and delivery.  (0.52) 
True (95) 0.22 
Taking antiretroviral therapy can reduce a child's risk of becoming HIV infected during 
breastfeeding.  (0.55) 
True (90) 0.21 
If a person takes antiretroviral therapy and has a low viral load, they may be less likely to 
transmit the virus through having sex with an HIV-negative partner. (0.53) 
True (26) 0.39 
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Continued Psychometric Scale Cronbach's (alpha score bolded if greater than 0.7) 
HIV/Aids Knowledge Inventory (Alpha = 0.40) 
Question (Item Total Correlation) Percentage correct (%) Alpha with item missing 
Is HIV/AIDS spread by kissing? (0.30) No (97) 0.38 
Must a person have many partners to get HIV? (0.32) No (88) 0.4 
Can a pregnant woman give HIV/AIDS to her baby? (0.54) Yes (68) 0.34 
Is HIV the virus that causes AIDS? (0.45) Yes (82) 0.37 
Is there a cure for HIV/AIDS? (0.30) No (90) 0.4 
Are there any medications a woman can take to protect her baby from 
getting HIV/AIDS? (0.37) 
Yes (93) 0.37 
Can a woman give HIV/AIDS to her baby during breast feeding? (0.53) Yes (33) 0.35 
Does formula feeding reduce the risk of a baby getting HIV? (0.48) Yes (29) 0.37 
Do caesarian sections reduce the risk of a baby getting HIV? (0.39) Yes (17) 0.39 
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Appendix B 
 
Spearman’s Rank Correlation Matrix of Study Adherence Measures  
 Number of Missed Doses 
in the last 30 days 
Rate adherence since 
initiation 
Rate adherence in last 
30 days 
In the last 30 days, rate 
how good a job you did 
in taking your ARVs 
How hard is it to take 
your medication as you 
are supposed to 
Number of Missed Doses 
in the last 30 days 
1     
Rate adherence since 
initiation 
-0.24 1    
Rate adherence in last 
30 days 
-0.48 0.75 1   
In the last 30 days, rate 
how good a job you did 
in taking your ARVs 
-0.46 0.56 0.67 1  
How hard is it to take 
your medication as you 
are supposed to 
-0.23 0.43 0.52 0.55 1 
 
 
The above table shows a correlation matrix between the self-reported measures of association used in this study. All of the correlations were statistically significant, 
despite the majority of them showing only weak to moderate correlations. The main outcome measure, number of missed doses in the last 30 days, was kept as a 
numerical variable for this particular analysis, with a range of 0 to 30 missed doses. It has a negative correlation with all of the other reported measures, meaning 
that as a participant reports missing each additional dose, their self-report in other areas gets worse. The strongest correlation was observed between the rating of 
adherence in the last 30 days and since initiation (0.75). This strong positive correlation provides a good idea of how adherence in the last 30 days relates to a 
person’s adherence history, and how they are nested together despite the different time frames. This could mean that adherence changes little over time, or it could 
mean that how well a person recalls taking their medication is affected by how well they have been taking it recently. 
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8400; Fax: 978-750-4470; Web: www.cooyrig ht.com ; E-mail: customercare@cooyriqht.com. 
For permissions to reuse the material for other purposes: Please go to the Journal website and 
click the "Permissions" link above the title of the paper in the abstract or html window for the 
relevant article. Alternatively, send an e-mail to customercare@copyriqht.com or e-mail 
journalpermissions@lww.com . Translation Rights & Licensing queries: Please contact Silvia 
Serra, Translations Rights, Licensing & Permissions Manager, Wolters Kluwer Health (Medical 
Research) Ltd, 250 Waterloo Road, London SE1 8RD, UK. Phone: +44 (0)207 981 0600; E-
mail: Silvia.Serra@wolterskluwer.com . Any permissions fees that might be required by the 
copyright owner are the responsibility of the authors requesting use of the borrowed material, 
not the responsibilit y of Lippincott Williams & Wilkins. 
PREPARATION OF MANUSCRIPT 
Manuscripts that do not adhere to the following instructions will be returned to the 
corresponding author for technical revision before undergoing peer review. 
ARTICLE LIMITATIONS - BEGINNING WITH JULY 15, 2010 SUBMISSIONS: 
I Limitations II Abst racts 
3500 words + 5 figures/tables - if Structured; 
·~ more then use Supplemental 250 words Digital Content 
Implementation and 3500 words + 5 figures/tables - if Structured; Operational Research more then use Supplemental 250 words (published online only) Digital Content 
Rapid Communications 2000 words + 2 figures/tables Unstructured, 150 words 
3000 words + 2 figures/tables Unstructured; 150 words 
Brief Reports 2000 words + 2 figures/tables Unstructured; 100 words 
Letter to the Editor 11500 words; 1 figure/table II none (published online only) 
I 
I 
*If a figure/table is more than one page it will count for multiple figures (ie: if 1 figure totals 2 
pages it will count as 2 figures; if 1 figu re takes 3 page, it will total 3 figures, etc.) 
ARTICLE TYPES 
Original Articles 
The above guidelines apply to the original article format. Articles should be limited to 3500 
words + 5 figures/tables. If addit ional space is needed, then use Supplemental Digital Content 
options. There should be a structured abstract of 250 words or less. 
Implementation and Operational Research ( NEW ARTICLE TYPE) 
JAIDS is now accepting manuscripts for a new focus area of interest: Implementation and 
Ooerational Research. In the context of HIV/AIDS with advances in HIV therapy and care, 
expansion of global access to treatment, care and prevention Implementation and Operational 
Research, while having particular relevance to global health is an important domestic focus as 
well. However the lessons learned through this research discipline are particularly relevant to 
guiding best practices in low-resource settings as antiretroviral drug access is expanded. 
Articles that encompass the translation of knowledge, practices, and technologies into clinical 
care of adult and pediatric patients with HIV/AIDS and their evidence-based effectiveness in 
"real world settings" are of particular interest. 
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All manuscripts should be submitted through one of the existing three sections: Basic and 
Translational Science, Clinical Science, or Epidemiology and Prevention using the article type 
Implementation and Operational Research. Structure of article is the same as Original Article. 
If accepted for publication, articles are published ONLINE ONLY with titles appearing 
in the print and online edition table of contents. 
Rapid Communications 
Articles accepted as Rapid Communications will normally be published within 8 weeks of 
acceptance. When submitting a paper for consideration as a Rapid Communication, please 
adhere to the following guidelines: 
• Submit your paper to Editorial Manager and designate the article type as "Rapid 
Communication." Please indicate to the Editor in a cover letter file why the paper merits 
special attention. 
• The paper should not exceed 2000 words and 2 figures/tables. 
• The paper should include an unstructured abstract (150 words or less), key words, 
methods, results, discussion, and reference sections. 
• The title page should include the corresponding author's telephone and fax numbers and e-
mail address. 
• Authors will receive proofs of their article for review by e-mail and will be expected to 
return corrections by fax within 24 hours of receipt. Changes received after this deadline 
will not be accepted. 
Papers that are not accepted as Rapid Communications may be considered as full-length 
articles. 
Critical Reviews 
Papers reviewing the literature on a particularly timely and interesting topic will be considered 
for publication in JAIDS . Authors are encouraged to keep review articles to less than 3000 
words and 2 figures/tables with an unstructured abstract of 150 words or less. In general, 
review articles written as work-for-hire by industry employees will not be considered for 
publication. All funding, writing assistance, and other relationships to possibly conflicted 
sources must be fully disclosed at the time of submission. 
Brief Reports 
Brief Reports are short versions of clinical studies. They represent observations that are 
preliminary, speak for themselves, or offer new insight into a recognized condition. 
Submissions should not exceed 2000 words + 2 figures/tables with an unstructured abstract of 
100 words or less. 
Letters to the Editor 
Letters to the Editor can provide additional comment on an article published in JAIDS, or can 
be a very concise report on study findings. Letters should be no more than 1500 words and 1 
figure/table. Beginning with July 15, 2010 submissions, Letters to the Editor will be 
published ONLINE ONLY. Title will appear in print and online edition table of 
contents. 
Online Submission 
Manuscript files must be uploaded into the Editorial Manager online interface. Most word-
processing file formats are acceptable. Editorial Manager will then create PDF files of the 
authors' submission, and the author must view and approve the files before they will be 
submitted to the editorial office. Please be sure that the manuscript file contains complete text 
for your submission (title page and abstract), as this is the file that will be downloaded by the 
reviewers and publisher. Please see the sections below for instructions regarding Figure and 
Table files. 
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Once the paper has been accepted for publication, and final versions of the manuscript, figures, 
and table files have been uploaded to the Editorial Manager interface, PDF files will not be used 
for typesetting. This is important to note for Table and Figure files, which may lose formatting 
when converted to PDF, but will remain intact in their original file format. 
Title Page 
A title page must be included in the manuscript file. Include on the title page: a) complete 
manuscript title; b) authors' full names, academic degrees, and affiliations; c) name and 
address for correspondence, includ ing fax number, telephone number, and e-mail address; d) 
address for reprints if different from that of corresponding author; e) meetings at which parts 
of the data were presented (including title of conference, city, and date); f) sources of support; 
and g) a running head of no more than 40 characters. 
The title page must also include disclosure of funding received for this work from any of the 
following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes 
Medical Institute (HHMI); and other(s). 
Abstract and Key Words 
The abstract should be structured and limited to 250 words depending on article type. It must 
be factual and comprehensive. Limit the use of abbreviations and acronyms, and avoid general 
statements (eg, "the significance of the results is discussed"). List 3 to 6 key words or phrases. 
Text 
Organize the manuscript file into sections with appropriate section headings. The sequence 
should be as follows: title page, abstract/key word page, introduct ion, methods, results, 
discussions, acknowledgments, references, tables, figures and figure captions. 
Authors should type, whenever possible, all mathematical and chemical symbols, equations, 
and formulas, and identify a ll unusual symbols the first time they are used. Define 
abbreviations at first mention in text and in each table and figure. If a brand name is cited, 
supply the manufacturer's name and address (city and state/country). 
Abbreviations 
For a list of standard abbreviations, consult the Council of Biology Editors Style Guide 
(available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, MD 20814 ) or 
other standard sources. Write out the full term for each abbreviation at its first use unless it is 
a standard unit of measure. 
References 
The authors are responsible for the accuracy of the references. Key the references (double-
spaced) at the end of the manuscript. (If using End Note, set the sty le output to JAMA.) Cite 
references in text in order of appearance. Cite unpublished data, such as papers submitted but 
not yet accepted for publication, or personal communications, in parentheses in the text. If 
there are more than 3 authors, list only the first 3 authors and then use et al. Refer to the List 
of Journals Indexed in Index Medicus for abbreviations of journal names. Sample references 
are given below : 
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5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial 
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8. Koenig L, Ellerbrock T, Pratt-Palm ire M, et al. Prospective predictors of medication 
adherence: a study of the first six months of highly active antiretroviral therapy (HAART) using 
electronic monitoring [WePeB5818]. Presented at: XIV International AIDS Conference; 2002; 
Barcelona. 
Figures 
Cite figures consecutively in the text, and number them in the order in which they are 
discussed . Submit all artwork in camera-ready form through Editorial Manager. Authors must 
submit figures as separate electronic files. High-quality hard copies may be requested once the 
manuscript has been accepted for publication. Lettering should be large enough that it will 
remain legible after figure reduction ; typewritten or unprofessional lettering is unacceptable. 
Figure parts (A, B, C) may be left unlabeled (but clearly marked on back) for professional 
placement by the journal's printer. 
Figure Legends 
Legends must be submitted for all figures. They should be included in the manuscript file, 
should be brief and specific, and should appear on a separate manuscript page after the 
references. Use scale markers in the image for electron micrographs, and indicate the type of 
stain used. 
Color Figures 
The journal accepts for publication color figures that will enhance an article. Authors who 
submit color figures will receive an estimate of the cost for color reproduction. If they decide 
not to pay for color reproduction, they can request that the figures be converted to black and 
white at no charge. 
Digital Figures 
A) Creating Digital Artwork 
1. Learn about the publication requirements for Digital Artwork : http: fll inks.lww .com/ES/A42 
2. Create, Scan and Save your artwork and compare your final figure to the Digital Artwork 
Guideline Checklist (below). 
3. Upload each figure to Editorial Manager in conjunction with your manuscript text and tables. 
B) Digital Artwork Guideline Checklist 
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Here are the basics to have in place before submitting your digital artwork: 
• Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XlS) files. High resolution 
PDF files are also acceptable. 
• Crop out any white or black space surrounding the image. 
• Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of at 
least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT, XLS) file. 
• Photographs, radiographs and other halftone images must be saved at a resolution of at 
least 300 dpi. 
• Photographs and radiographs with text must be saved as postscript or at a resolution of at 
least 600 dpi. 
• Each figure must be saved and submitted as a separate file. Figures should not be 
embedded in the manuscript text file. 
Remember: 
• Cite figures consecutively in your manuscript. 
• Number figures in the figure legend in the order in which they are discussed. 
• Upload figures consecutively to the Editorial Manager web site and enter figure numbers 
consecutively in the Description field when uploading the files. 
Supplemental Digital Content (SOC) 
Authors may submit SDC via Editorial Manager to LWW journals that enhance their article's 
text to be considered for online posting. SDC may include standard media such as text 
documents, graphs, audio, video, etc. On the Attach Files page of the submission process, 
please select Supplemental Audio, Video, or Data for your uploaded file as the Submission 
Item. If an article with SDC is accepted, our production staff will create a URL with the SDC 
file. The URL will be placed in the call-out within the article. SDC files are not copy-edited by 
LWW staff, they will be presented digitally as submitted. For a list of all available file types and 
detailed instructions, please visit http://links.lww.com/A142. 
SOC Call-outs 
Supplemental Digital Content must be cited consecutively in the text of the submitted 
manuscript. Citations should include the type of material submitted (Audio, Figure, Table, etc.), 
be clearly labeled as "Supplemental Digital Content," include the sequential list number, and 
provide a description of the supplemental content. All descriptive text should be included in the 
call-out as it will not appear elsewhere in the article. 
Example: 
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental 
Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive. 
List of Supplemental Digital Content 
A listing of Supplemental Digital Content must be submitted at the end of the manuscript file. 
Include the SDC number and file type of the Supplemental Digital Content. This text will be 
removed by our production staff and not be published. 
Example: 
Supplemental Digital Content l.wmv 
SOC File Requirements 
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 10 
MBs, authors should first query the journal off ice for approval. For a list of all available file 
types and detailed inst ruct ions, please visit http://links.lww.com/Al42. Please do not submit 
pdfs. 
Tables 
Create tables using the table creating and editing feature of your word-processing software 
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(eg, Word, Word-Perfect). Do not use Excel or comparable spreadsheet programs. Group all 
tables together and upload them in a separate file. Cite tables consecutively in the text, and 
number them in that order. Key each on a separate sheet, and include the table title, 
appropriate column heads, and explanatory legends (including definitions of any abbreviations 
used). Do not embed tables within the body of the manuscript. They should be self-explanatory 
and should supplement, rather than duplicate, the material in the text. 
Style 
Pattern manuscript style after the American Medical Association Manual of Style (9th edition). 
Stedman's Medical Dictionary (28th edition) and Merriam-Webster's Collegiate Dictionary (11th 
edition) should be used as standard references. Refer to drugs and therapeutic agents by their 
accepted generic or chemical names, and do not abbreviate them. Use code numbers only 
when a generic name is not yet available. In that case, supply the chemical name and a figure 
giving the chemical structure of the drug. Capitalize the trade names of drugs and place them 
in parentheses after the generic names. To comply with trademark law, include the name and 
location (city and state in USA; city and country outside USA) of the manufacturer of any drug, 
supply, or equipment mentioned in the manuscript. Use the metric system to express units of 
measure and degrees Celsius to express temperatures, and use 51 units rather than 
conventional units. 
Obligation to Register Clinical Trials 
JAIDS has adopted the standards of the International Committee of Medical Joumal Editors 
with regard to the registration of clinical trials. As a condition of consideration for publication , 
data from research projects "prospectively assigning human subjects to intervention or 
concurrent comparison or control groups to study the cause-and-effect relationship between a 
medical intervention and a health outcome" must be registered in a public trials registry. The 
Protocol Registration System (http://orsinfo.clinicaltrials.gov/) offered through the U.S. 
National Inst itutes of Health is one such registry. 
GenBank Accession Numbers 
When manuscripts include or describe original nucleotide or amino acid sequence data, the 
sequence must be submitted to the GenBank/EMBL/DDBJ sequence database and an accession 
number obtained from them . This accession number must be returned to the journal, where it 
will be placed after the Key Words on the title page in the printed article. URLs for the 3 
members of the International Nucleotide Sequence Database Collaboration 
(GenBank/EMBL/DDBJ) are as follows (respectively) : http://www.ncbi.nlm.nih.gov/Banklt/, 
http ://www .ebi.ac.uk/embl!, http: flwww .ddbj .niq .ac.jp/ . 
Open access 
LWW's hybrid open access option is offered to authors whose articles have been accepted for 
publication. With this choice, articles are made freely available online immediately upon 
publication. Authors may take advantage of the open access option at the point of acceptance 
to ensure that this choice has no influence on the peer review and acceptance process. These 
articles are subject to the journal's standard peer-review process and will be accepted or 
rejected based on their own merit. 
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for JAIDS is $3,100. The article processing charge for 
authors funded by the Research Councils UK (RCUK) is $3,900. The publication fee is charged 
on acceptance of the article and should be paid within 30 days by credit card by the author, 
funding agency or institution. Payment must be received in full for the article to be published 
open access. 
Authors retain copyright 
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Authors retain their copyright for all articles they opt to publish open access. Authors grant 
LWW a license to publish the article and identify itself as the original publisher. 
Creative Commons license 
Articles opting for open access will be freely available to read, download and share from the 
time of publication. Articles are published under the terms of the Creative Commons License 
Attribution-NonCommerical No Derivative 3.0 which allows readers to disseminate and reuse 
the article, as well as share and reuse of the scientific material. It does not permit commercial 
exploitation or the creation of derivative works without specific permission. To view a copy of 
this license visit: http://creativecommons.org/licenses/by-nc-nd/3.0 . 
Compliance with NIH, RCUK and other research funding agency accessibility 
requirements 
A number of research funding agencies now require or request authors to submit the post-print 
(the article after peer review and acceptance but not the final published article) to a repository 
that is accessible online by all without charge. As a service to our authors, LWW identifies to 
the National Library of Medicine (NLM) articles that require deposit and transmits the post-print 
of an article based on research funded in whole or in part by the National Institutes of Health, 
Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The revised 
Copyright Transfer Agreement provides the mechanism. LWW ensures that authors can fully 
comply with the public access requirements of major funding bodies worldwide. Additionally, all 
authors who choose the open access option will have their final published article deposited into 
PubMed Central. 
RCUK funded authors can choose to publish their paper as open access with the payment of an 
article process charge, or opt for their accepted manuscript to be deposited (green route) into 
PMC with an embargo. 
With both the gold and green open access options, the author will continue to sign the 
Copyright Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that the 
author is fully compliant with the requirements. After signature of the CTA, the author will then 
sign a License to Publish where they will then own the copyright. 
It is the responsibility of the author to inform the Editorial Office and/or LWW that they have 
RCUK funding. LWW will not be held responsible for retroactive deposits to PMC if the author 
has not completed the proper forms. 
Page Proofs and Corrections 
PDF files of the copyedited, typeset pages and support documents (eg, reprint order form) will 
be sent to the corresponding author via e-mail. Complete instructions will be provided with the 
e-mail for downloading and printing the files and for faxing the corrected pages to the 
publisher. It is the author's responsibility to ensure that there are no errors in the proofs. 
Changes that have been made to conform to journal style should be allowed to stand if they do 
not alter the authors' meaning. Only critical changes improving the accuracy of the content will 
be made. Changes that are stylistic or are a reworking of previously accepted material will not 
be allowed. The publisher reserves the right to deny any changes that do not affect the 
accuracy of the content. Authors may be charged for alterations to the proofs beyond those 
required to correct errors or to answer queries. Proofs must be checked carefully and 
corrections faxed within 24 to 48 hours of receipt, as requested in the cover letter 
accompanying the page proofs. 
Reprints 
Reprint orders should be submitted to the Reprints Department (1 -800-341-2258 or 
reprintsgroup@LWW .com). Payment for reprints or a purchase order number must accompany 
your order form . Orders without these cannot be fulfilled. More information can be obtained at 
http://www .lww .com/periodicals/author-reprints/ 
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